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The completion of the human genome project has led to a flood of new
genetic data, that has proved surprisingly hard to interpret. Network “guilt by as-
sociation” (GBA) is a proven approach for identifying novel disease genes based on
the observation that similar mutational phenotypes arise from functionally related
genes.
However, GBA has been shown to work poorly in genome-wide association
studies (GWAS), where many genes are somewhat implicated, but few are known
with very high certainty. In the first part of this work, I resolve this by explic-
itly modeling the uncertainty of the associations and incorporating the uncertainty
for the seed set into the GBA framework. I demonstrate a significant boost in the
power to detect validated candidate genes for Crohns disease and type 2 diabetes
by comparing the predictions from my method to results from follow-up meta-
analyses, with incorporation of the network serving to highlight the JAK–STAT
pathway and associated adaptors GRB2/SHC1 in Crohns disease and BACH2 in
type 2 diabetes. Consideration of the network during GWAS thus conveys some of
vii
the benefits of enrolling more participants in the GWAS study. More generally, we
demonstrate that a functional network of human genes provides a valuable statis-
tical framework for prioritizing candidate disease genes in GWAS-based studies.
Furthermore, functional gene networks are not the only kind of information
that can be used to predict gene–phenotype associations. In the second part of this
thesis, I show that gene–phenotype associations in model species from species as
distantly related to humans as E. coli is another valuable source of information, that
can be mined using methods similar to those used in recommender systems.
Finally, in the last part of this thesis, I present a machine learning formal-
ism that combines the functional gene network and model species phenotype in-
formation. I show that this approach outperforms the state of the art methods for
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Chapter 1
Background – The Genetics of Human Disease
1.1 Introduction
The completion of the Human Genome Project [1, 2] and the HapMap proj-
ect [3] gave us a map of common human genetic variation that has enabled an in-
credible growth in our understanding of the genetics of many human diseases over
the last decade. Genome-wide association studies (GWAS), which assay hundreds
of thousands of mutations in thousands of patients, have identified risk alleles for
many common diseases (see, for example [4]), and exome sequencing enables un-
biased discovery of rare disease-causing mutations, such as the discovery of the
causal gene for the rare Mendelian disorder Miller syndrome [5].
Meanwhile, our growing understanding of genetics and molecular biol-
ogy has enabled an alternative approach to the genome-wide, unbiased techniques
epitomized by GWAS and exome sequencing. Sequencing of candidate genes have
identified mutations underlying many diseases, such as Rett syndrome [6], and
ever better model systems for studying human diseases have been developed in
mouse, fly, fish, and many other model species. A very successful example of
this approach are so-called “guilt-by-association” methods, where new candidate
genes are predicted for diseases by their association to already known causal genes
for the disease. This association can be of many forms, such as protein–protein
1
interactions, co-expression, genetic interactions, and so on.
One particular method that has been pursued by this lab, is to use an in-
tegrative Bayesian approach to encode many different kinds of functional associa-
tions into a genome-wide functional gene–gene interaction network, first developed for
baker’s yeast by Edward Marcotte [7] and Insuk Lee [8]. These functional gene
networks have been shown to be effective tools for finding new genes involved
in, for example, gene loss-of-function phenotypes in yeast [9], and RNAi knockout
phenotypes in nematodes [10]. In this work, we show that GBA using HumanNet,
a new functional gene–gene interaction network for humans, can also be used to
find new human disease genes. In particular, I will present a method for using
network GBA when the labels are “fuzzy”, that is, when we have a large number
of genes that are likely to be involved in a disease, but not certain. This allows us
to bring network-guided GBA to the GWAS setting, and identify pathways and
mechanisms likely to be involved in Crohn’s disease and type 2 diabetes.
Another form of association that has been used successfully to identify dis-
ease genes in human disease is the phenolog approach proposed by Kris McGary et
al. [11], who identify pairs of phenotypes (which they call phenologs) in different
organism that have an unusually high number of genes in common. They hypo-
thesize that this etiological overlap is due to some kind of evolutionarily conserved
mechanism, and that the genes involved in only one of the phenotypes in the phe-
nolog pair should therefore be good candidate genes for the other one. In this
work, I extend this framework to draw on multiple distantly related phenotypes
for predicting new genes for human diseases.
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Finally, to conclude this dissertation, I will present a machine learning frame-
work that combines HumanNet and the phenolog idea into a single, unified pre-
diction method. I will show the power of this combined framework for predicting
gene – disease associations, and use it to highlight a weakness in one of the schemes
commonly used to test the performance of disease gene prediction methods.
To set the context for this work, I will first give a very brief overview of
the molecular biology and genetics concepts that are necessary to understand this
work. I will then present the results in three chapters, one chapter on HumanNet
and GWAS, one chapter on predicting disease genes using multiple phenotypes
from distantly related species, and one chapter on how to combine HumanNet and
multiple species, and on how these results should be tested.
1.2 Some molecular biology
Since Watson and Crick [12], what is known as the central dogma of molecular
biology has held that there are three classes of information bearing biopolymers,
DNA, RNA, and proteins, and that information can flow between these in nine
possible ways [13], of which three are general (normal), three special (unusual)
and three unknown (never observed).
DNA (deoxyribonucleic acid) and RNA (ribonucleic acid) are both large
molecules, made up of long chains of nucleotides. For DNA, these are adenine (A),
cytosine (C), thymine (T) and guanine (G). For RNA, uracil (U) is used instead of
thymine. These nucleotides come in two parings: A-(T/U) and C-G. In DNA, two
chains (called strands) combine into a double helix with a perfect complement, so
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that across from each A in one chain there is a complementary T in the other, and
across from each C there’s a G.
During transcription, molecules called RNA polymerase transcribe some
short set of instructions written by the DNA into a RNA molecule called a mes-
senger RNA (or mRNA for short). The mRNA is then translated into a string of
amino acids called a protein by molecular machines called ribosomes. The proteins
are involved in most of the actual work in the cell — e.g. as enzymes that catalyze
different reactions, as scaffolds in different structures in the cell, and by binding to
RNA or DNA. A stretch of DNA that codes for a specific protein is often called a
gene.1
1.3 Interactions and pathways
Proteins often interact with each other in different ways, either transiently
(e.g. by phosphorylating a different protein) or on a more long term basis (e.g.
by forming a long-lived complex with another protein). They are also involved in
the regulation of protein production in many ways, e.g. by binding to DNA to up
or down regulate the expression of genes. Often, interactions of different kinds are
strung together into complex regulatory mechanisms called pathways, which can be
involve either protein-protein interactions (such as phosphorylation cascades and
other signaling mechanisms) or many levels of protein-DNA interactions (such as
1This is a rather imprecise use of the term. Geneticists define a gene to be a unit of inheritance,
which could involve any kind of structure in the DNA. Thus, for many traits the stretch of DNA that
regulates the trait does not code for any other molecule at all, but might instead be involved in the
regulation of the expression of a protein coding gene. I will, however, follow the standard convention
of the field and use the term sloppily.
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when a transcription factor up regulates the expression of another transcription
factor), or combinations of the two. In this work, I will refer to both of these kinds
of interactions as functional gene-gene interactions.
1.4 Haplotypes, and the organization of DNA
When DNA gets copied, sometimes mistakes slip in which are then inher-
ited by all successive copies. Such mistakes are called mutations, and can both
increase and decrease the fitness of the organism — sometimes depending on the
environment the organism finds itself in.
DNA is organized into large molecules called chromosomes, and every hu-
man cell (except for germ line cells) carries two similar, but not identical copies of
each chromosome — one inherited from the father, and one from the mother. Cells
that carry two copies of each chromosome are called diploid, and cells that carry a
single copy of each chromosome are called haploid.
During sexual reproduction, cells undergo a special kind of cell division
called meiosis, in which a diploid mother cell produces haploid daughters. In
men, these daughter cells are sperm cells, in women, egg cells. During meiosis,
the DNA in each chromosome recombines with the corresponding stretch of DNA
in the other copy of the same chromosome, which causes the chromosomes in the
daughter cells to be a mix of the chromosomes in the mother cell, with alternating
stretches of DNA derived either from the paternally or the maternally inherited
chromosome.
Because of this crossover process, if two variants exist in an individual, they
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are likely to be inherited together if they are located close to each other on the actual
chromosome. If a carrier of such a close pair is reproductively successful, a large
fraction of the population might end up carrying both mutations together. These
blocks of co-inherited genetic variants are called haplotypes. As generations go by,
the linkage between the variants in a haplotype block will get weaker and weaker
due to repeated crossover. Therefore, the linkage between different loci will be
weaker the older a population is. We therefore have a clearer haplotype structure
in e.g. European and East Asian populations (that have undergone quite recent
population expansions during the agricultural revolution) than in most aboriginal
African populations, where the haplotypes have been mixed up through repeated
mating.
1.5 Single nucleotide polymorphisms
Single nucleotide polymorphisms (SNPs, pronounced “snips”) are the most
common kind of genetic polymorphism in terms of the number of occurrences [14].
In a SNP, a mutation has occurred at a certain position in the genome that changes
one letter of the genetic alphabet into another one. This variant has then spread
out into the general population, and now exists at a certain percentage in the pop-
ulation studied, while the original makes up for the rest. We might not right now
know which of these two variants is the original and which is newer, but we can
measure which one is more common, and which one is rarer. The more common
version is called the major allele, and the less common the minor allele.
After the completion of the Human Genome Project [1, 2], one of the major
6
Figure 1.1: Population structure arises from mutations in ancestors to the present
population. Here we show how mutations propagate in a haploid population. Par-
ent – offspring relationships are shown with arrows, and mutated nucleotides are
shown in a contrasting color. Haplotypes arise when an individual sees consid-
erable reproductive success, like the leftmost individual in the second generation
above; all its offspring share the same C → G mutation, which defines the haplo-
type.
7
endeavors in human genetics has been the mapping of the common genetic vari-
ations in human beings, the so-called International HapMap Project [3]. HapMap
has identified millions of common SNPs (minor allele frequency (MAF) > 5%), and
also found which ones were strongly correlated. This allowed the construction of
a type of device called a SNP chip (reviewed in [15]).
A SNP chip is a microchip-like little device with about a million dots on
it. Each dot contains a piece of DNA also found on the genome, centered around
one of the common SNPs. For each SNP there are at least two dots, one for each
allele. By measuring which version a person’s DNA binds to, it is possible to de-
termine if the person is homozygous for the major version, the minor version or
heterozygous at that SNP. Since even early versions of these chips contained more
than a million such dots, one can easily measure hundreds of thousands of SNPs in
a single measurement. This, and the fact that each chip only costs a few hundred
dollars to make, has made large-scale measurement of genetic variations possible.
1.6 Genome-wide association studies, and the common disease — com-
mon variant hypothesis
Many common disease — for example diabetes, Crohn’s disease, obesity
and bipolar disorder — have strong hereditary components. In the years following
the completion of the human genome project, there was a lot of uncertainty over
how the genetic architecture of this hereditary component might be structured.
Two common schools of thought emerged: One, the common disease – common
variant (CDCV) hypothesis, and the common disease – rare variant (CDRV) hy-
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pothesis [16, 17]. The CDCV hypothesis posited that all humans harbored a large
number of genetic variants that each had a very minor effect on the disease risk.
Since no single variant significantly increased the risk that the bearer would de-
velop the disease, there was no strong selection against them. Only when someone,
by bad luck in the great lottery known as sexual mating, happens to draw many
more of the risk variants than most people, do they develop the disease.
The CDRV hypothesis on the other hand holds that mutations that increase
the risk for disease would be selected against, and we wouldn’t see many of them.
Instead, it hypothesized that the common diseases we see are caused by many
different mutations, that spontaneously arise every now and then. If they arise
in a type 1 diabetes gene, the unlucky bearer and his offspring are more likely to
develop diabetes, and if they occur in a bipolar disorder gene, the bearer is likely
to develop bipolar disorder. Since there is a selective pressure against having these
diseases, they will usually only persist for a few generations before they go extinct.
In this scenario, any single variant will be much rarer than the ones hypothesized
by the CDCV hypothesis, but will have a much stronger effect on the unfortunate
individual who happens to carry them.
With the advent of the SNP chips described above, we were given the tools
to experimentally test the CDCV hypothesis. A type of study, called a Genome
Wide Association Study (GWAS) was devised [15]. Most GWAS are planned using
a case-control design. In a case-control study, about half of the participants have
developed the disease (the cases) and the other half are healthy (the controls). Each
participant’s genetic make-up is measured using a SNP chip that is designed to
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be as unbiased as possible in the SNPs it measures, and the cases and controls are
compared. If the distribution of a SNP differs between the cases and the controls,
it is likely that some genetic variant in the vicinity of this SNP is causing people to
develop the disease. For a more complete overview of GWAS, see the reviews in
[18] or [19].
The outcome of these GWAS has met mixed reception. On the one hand,
they have identified hundreds of new gene associations for a wide range of disor-
ders. On the other hand, they can only explain a very small fraction of the known
heritability of these diseases. This has led to widespread debate over where this
“missing heritability” might be hidden [20]. Could it be in non-additive interac-
tions between the different loci, so called epistatic interactions? Is it because the
diseases themselves are poorly characterized? Or is the CDRV hypothesis partially
true, and rare, but strong, mutations account for the heritability that is “missing”?
For now, the jury is still out, but there is probably some partial truth to all of the
above explanations.
10
Figure 1.2: A C/G SNP in a haploid population. Note that real human populations
have two copies of each gene. In a GWAS, this SNP is analyzed to see if it’s distri-
bution differs significantly between the case and control population. Since a GWAS




Prioritizing candidate disease genes by network-based
boosting of genome-wide association data
The first major part of my work makes use of HumanNet to improve the
predictions of GWAS. This chapter is adapted from the paper “Prioritizing candi-
date disease genes by network-based boosting of genome-wide association data”,
which I published with Insuk Lee as joint first author in Genome Research, 2011
[21].
In this paper, Insuk Lee was responsible for the construction of the network
and the basic analyses of how phenotypes can be predicted using the network,
Peggy Wang compared different network prediction algorithms, and I adapted the
network GBA strategies to the GWAS setting. Insuk, Edward and I wrote the paper
together.
2.1 Introduction
Causal genes remain extraordinarily difficult to identify in most genetic
diseases, and in particular, in highly polygenic disorders, for which current ap-
proaches are most limited [22], identifying causal genes is a major barrier to progress
in understanding these diseases. More generally, traditional linkage analyses have
mapped causal genes for many diseases, often using positional cloning, but these
12
methods are difficult and time-consuming [23]. However, genome-wide associa-
tion studies (GWAS) have opened the way to unbiased discovery of large numbers
of disease genes in a more efficient manner.
A typical GWAS analysis involves comparing case and control individuals
at selected single nucleotide polymorphisms (SNPs) or, more recently, copy num-
ber variants (CNVs). SNPs representing common haplotype blocks are measured
genome-wide (at approx. 500,000 1,000,000 locations), and the disease-associated
genetic markers are identified (reviewed in [24]). The SNPs that show association
strong enough to surpass a genome- wide significance threshold are then analyzed
for chromosomal proximity to genes that might cause the disease, or otherwise
affect its etiology. However, even though the data from GWAS support a great
number of loci involved in common diseases, it is hard to separate many of the
causal genes from the background noise of the hundreds of thousands of SNPs in
the assay. Consequently, GWAS suffer from a lack of statistical strength, requiring
large test populations to overcome the large multiple hypothesis correction needed
in evaluating hundreds of thousands of candidate loci.
The lack of sufficient statistical power forces GWAS studies to ignore weaker
loci, focus primarily only on the strongest genetic effectors, and genotype thou-
sands of individuals (e.g., [4]). Moreover, the combinatorial effects of multiple dis-
ease genes are often not simply additive but epistatic [15, 25, 26], further hampering
their discovery. Simply considering pairs of interacting loci increases the strength
of associations required by orders of magnitude so as to be able to overcome the
multiple testing criteria, requiring tens of thousands of individuals [27]. Rarely has
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genetic association to allele triplets (or higher) been examined by these or any other
approaches. Linear additive models have been successfully built, most notably for
54 alleles useful for predicting human height [28–30], one of the first quantitative
human traits successfully addressed to this degree. Finding these alleles nonethe-
less required genotyping 63,000 individuals over the course of 3 studies, each ex-
plaining ¡4% of the variance in height. Recent analysis of approx. 300,000 SNPs,
without regard to the significance of their association, demonstrated that a total of
45% of the variance in height could potentially be explained, with most effects too
small to pass significance tests [31].
However, the polygenic nature of a disease may also offer potential op-
portunities to more efficiently discover new and relevant genes. In particular, we
might expect that the genes associated with a disease will often organize into path-
ways or functional groupings linked to the disease formation and progression.
Thus, knowing some disease genes in advance, it may occasionally be possible to
apply guilt-by-association (GBA) in gene networks (reviewed in [32]). In particu-
lar, it is now possible to construct large gene network models, as has been done e.g.
for yeast, worms, plants, mice, and humans, summarizing thousands of functional
associations among genes, as reviewed in [33–36]. Gene pairs are coupled in these
networks if they are inferred to participate in the same biological process [7] and
may have corresponding measures of confidence [8, 37–40]. GBA in such networks
has been shown to correctly identify disease and phenotype-linked genes based on
their network connections to previously known genes (e.g., [9, 10, 41–46]), based on
the observation that genes involved in a common biological process often tend be
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associated with similar mutational phenotypes, as seen e.g. in [10, 41, 42, 47].
In principle, the GWAS-based association of genetic loci with a disease and
the functional association of genes into pathways represent independent sets of
observations that can be logically combined to improve identification of relevant
disease genes. For example, networks have been applied to search for interacting
loci in human GWAS data [48, 49] and in yeast [50], to identify GWAS- and cancer
genome-enriched pathways [51, 52], and to rank genes in implicated chromosomal
intervals [53–55]. Other studies have looked at previously studied pathways for a
disease, and tried to improve the ranking of the candidate genes using this infor-
mation (e.g. [56, 57]; more reviewed in [58]). Here, we have tested and expanded
the general validity of the approach of using functional networks for prioritizing
candidate disease genes. We propose a theoretical framework for combining the
large-scale, unbiased pathway and association information encoded by functional
gene networks and GWAS studies respectively, showing improvements in perfor-
mance as judged by data from GWAS meta-analyses.
First, we describe the construction of a functional network for human genes.
This network spans 87% of validated protein coding genes, and provides strong
predictive power for a majority of currently known genetic diseases. We eval-
uate six alternate approaches for prioritizing candidate disease genes using this
network, and demonstrate the strongest overall performance with algorithms re-
lated to Googles PageRank. We then show that this network, in conjunction with
genome-wide association data for Type 2 diabetes and Crohns disease, boosts the
identification of disease-associated genes that were discovered in later meta-analyses.
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This work suggests both a specific strategy and a general path to future improve-
ments for the interpretation of GWAS data. Taken together, our work demonstrates
that a high-quality functional network for human genes can provide a powerful re-
source for identifying causal genes in human disease.
2.2 Results
HumanNet: an extended functional gene network for H. sapiens
To test the ability of functional networks to improve gene association stud-
ies, we first constructed a genome-scale functional network for human genes. Di-
verse distinct lines of evidence, spanning human mRNA co-expression, protein-
protein interactions, protein complex, and comparative genomics datasets, in com-
bination with similar lines of evidence from orthologs in yeast, fly, and worm, were
analyzed, using an approach previously developed and validated for yeast [8, 59],
C. elegans [10, 60] and Arabidopsis [46]. In total, 21 large-scale genomics and pro-
teomics datasets from the 4 species (see Methods, Tables S1 and S2) were integrated
into a functional gene network spanning 476,399 scored functional couplings be-
tween 16,243 (87%) of validated human protein encoding genes (Figure 2.1).
HumanNet predicts cellular loss-of-function phenotypes
To evaluate the predictive power of the new network, we first examined
cellular-level phenotypes. Many human diseases reflect failures of core cellular
machinery, e.g. failures of metabolism, DNA repair, replication, etc. For exam-
ple, hereditary nonpolyposis colorectal carcinoma arises from mutations in DNA
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Figure 1 
Figure 2.1: Construction of a genome-scale human gene network, HumanNet. 21 diverse
functional genomic and proteomic data sets (Table 1) were evaluated for their tendencies
to link genes in the same biological processes. Pairwise gene linkages derived from the
individual datasets were then integrated into a composite network of higher accuracy and
genome coverage than any individual data set. The integrated network (HumanNet) con-
tains 476,399 functional linkages among 16,243 (86.7%) of the 18,714 genes encoding vali-
dated human proteins. The plot x axis indicates the log-scale percentage of the 18,714 genes
covered by functional linkages derived from the indicated datasets (curves); the y axis in-
dicates the predictive quality of the datasets, measured as the cumulative log likelihood
of linked genes to share Gene Ontology (GO) biological process annotations, tested using
0.632 bootstrapping and plotted for successive bins of 1,000 linkages each (symbols). Data
sets are named as XX-YY, where XX indicates species of data origin (CE, C. elegans; DM,
D. melanogaster; HS, H. sapiens; SC, S. cerevisiae) and YY indicates data type (CC, cocitation;
CX, mRNA coexpression; DC, domain cooccurrence; GN, gene neighbor; GT, genetic in-
teraction; LC, literature-curated protein interactions; MS, affinity purification/mass spec-
trometry; PG, phylogenetic profiles; PI, fly protein interactions; TS, tertiary structure; and
YH, yeast two-hybrid). Detailed descriptions are listed in Table S1.
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Table 2.1: Selected top-ranked Crohns disease and type 2 diabetes genes for
which network data added support to GWAS evidence, measured as an increase
in odds (prior=1.7 for each).
Crohn’s disease
Gene name New rank Original rank Log odds increase Interaction partners
NOD2 1 1 0
ATG16L1 2 2 0.53 CAPN9
IL23R 3 3 0.76 STAT3
CYLD 4 4 0.52 TRAIP
PTPN2 5 6 0.76 STAT3
GRB2 7 99 3.63 DAG1, APP, STAT3,
DDK1, PPP2R2B
STAT3 8 17 1.88 IL23R, PTPN2, GRB2
BSN 9 9 0.61 CAMKV, ERC2
DAG1 11 21 1.6 TCTA, GRB2
PPM1K 16 125 2.27 CDK14, CAMKV, CLK3,
MAGI2
SHC1 17 6125 3.98 PTPN2, STAT3, DOK1, GRB2,
USP4,PTPN2, PPM1K
SRC 20 11633 4.38 MAGI2, DAG1, STAT3, GRB2,
USP4, PTPN2, PPM1K
CAPN9 22 18 0.58 ATG16L1
TRAIP 28 327 1.91 BATF, CREM, CYLD,
TRAIP,USP7
JAK2 38 3139 2.95 IL23R, STAT3, GRB2,
IL12RB2, PPM1K, MAGI2
Type 2 diabetes
Gene name New rank Original rank Log odds increase Interaction partners
TCF7L2 1 1 0
THBS2 2 5 0.36 ISLR
CDKAL1 3 2 0
TSPAN8 4 3 0
PARD3B 10 13 0.22 KIF23
KIF23 14 44 1.05 MELK, FAM49A, DYNCH1H1,
GTSE1, PARD3B
FAM49A 16 42 0.9 ANKS1B, KIF23, ANKS1A
ISLR 17 26 0.49 THBS2, ZNF532
BACH2 18 200 1.66 TCF7L2, PARD3B, CREB5
ANKS1A 23 30 0.32 FAM49A
XYLB 27 34 0.36 ATG7
MAGI2 29 65 0.67 ALK, CHUK, PRKG1, MELK,
DYRK1A
CDC42 35 191 1.18 PARD3B, ATG7
MELK 38 51 0.46 MAGI2, KIF23
CTNNB1 76 3099 1.88 ATG7, TCF7L2, LOH12CR1,
CHUK, MAGI2
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mismatch repair [61, 62], Zellweger syndrome arises from mutations in peroxisome
biogenesis [63], and leukoencephalopathy with vanishing white matter arises from
mutations in any of the subunits of translation initiation factor eIF2B [64, 65]. A net-
work for even a single eukaryotic cell will capture many of these basic processes,
and has the potential to prove predictive for genes for diverse human diseases.
We therefore investigated if the human gene network was predictive of cellular-
level mutational phenotypes, focusing on cell survival and proliferation pheno-
types from loss-of-function studies in cell culture.
We first asked if genes essential to cell viability could be accurately identi-
fied using the gene network. Schlabach and colleagues identified about 600 genes
that affect the viability and proliferation of normal human mammary epithelial
cells (HMEC) by using multiplex short hairpin RNA (shRNA) screening [66]. Al-
though assayed largely for proliferation defects, these genes are highly likely to
be essential for HMEC cell growth, given the incompletely penetrant phenotype
induced by shRNA knockdown [67]. We found that the essential HMEC genes
were, indeed, highly connected in HumanNet (Figure 2.2A), as assessed by cross-
validated receiver operating characteristic (ROC) analysis (see Methods). For ex-
ample, about 18% of all known essential genes, but only 2% of all genes not known
to be essential, are connected to known essential genes in HumanNet, a nine-fold
enrichment. From these results we conclude that essential genes can be predicted
on the basis of their connectivity to other essential genes in HumanNet.
This general level of predictability was also observed for more specific cel-
lular phenotypes. We tested if genes known to be required for HIV infection,
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A B
Figure 2.2: Genes associated with many phenotypes are highly connected in HumanNet.
A Essential genes were highly interconnected in HumanNet, and thus predictable from the
network, as shown by ROC analysis. Genes were ranked by their sum of network edge
weights to the known essential genes, measuring recovery of known essential genes (true
positives) and other genes (false positives) using leave-one-out cross-validation. B Specific
phenotypes are predictable by HumanNet. Genes involved in more specific cellular phe-
notypes – host factors required for HIV infection (HDF) [68], modulators of OCT4 (also
known as POU5F1) expression (Oct4-GI) [69], and synthetic lethal partners of activated
KRAS alleles (KRAS-SL) (Luo et al. 2009) – were also well predicted by their interconnec-
tivity in HumanNet, calculated as for A.
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as measured by large-scale RNAi knockdown [68], were predictable by guilt-by-
association in HumanNet. Indeed, they showed a moderate degree of predictivity,
at a level significantly higher than random chance (Figure 2.2B).
The essentiality and viral infectivity phenotypes described above are single
gene phenotypes, but yeast and worm gene networks have also proven generally
predictive for bigenic phenotypes, such as synthetic genetic interactions (e.g., [60]).
We therefore next asked if the human gene network could predict genetic inter-
actions, focusing on two large-scale RNAi screens performed in mammalian cell
culture. The first screen identified genes modulating expression of a core stemness
regulator Oct4 in mouse embryonic stem cells [69]. The second found genes acting
as synthetic lethal interaction partners with oncogenic KRAS mutants expressed in
a colorectal cancer cell line, screening for genes whose knockdown in the activated
KRAS background resulted in cellular lethality [70]. In both cases, genes identified
by the screens were well-predicted by guilt-by-association in HumanNet at rates
significantly higher than random expectation (Figure 2.2B). The high predictive
strength (AUC = 0.81) for KRAS interactors is particularly notable, as such genes
might be useful as cancer cell specific drug targets [70]. More generally, these tests
confirm that the human gene network is predictive of a variety of cellular level
loss-of-function phenotypes, including specific bigenic traits.
Genes linked to specific mouse mutational phenotypes and human diseases are
predictable by guilt-by-association in the network
The cellular-level results demonstrate that genes for cell viability and prolif-
eration phenotypes can be identified based on network connectivity in HumanNet.
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A further trend for genes linked in the network to share tissue-specific expression
patterns (Figure 2.3) implies that the network could potentially predict more spe-
cific organism-level mutational phenotypes as well. This notion has previously
been explored for human diseases by considering network connections among
known disease genes, prioritizing the genes most highly connected to the known
causal genes as being likely new candidate genes for that disease [9, 41, 42, 45], as
illustrated in Figure 2.4. Such approaches primarily consider direct network con-
nections to known disease genes, but related work on predicting gene function
from networks (reviewed in [71, 72]) has shown wide benefits of also appropriately
considering indirect network connections (e.g., as in [73]), and tests have confirmed
the utility of these so-called network diffusion algorithms for predicting RNAi phe-
notypes in worms and loss-of-function phenotypes in yeast cells [74]. Here, we
implemented a representative set of both types of algorithms, collectively termed
label propagation algorithms and chosen by their successful application in yeast
and worm networks [74], for inferring disease genes based on network connectiv-
ity, evaluating them for their overall predictive ability using cross-validation and
ROC analysis.
Specifically, we considered six methods of network label propagation. The
first are two methods that consider only direct network neighbors: (1) neighbor
counting [76], in which the genes with the most neighbors already linked to the
disease are most highly scored, and (2) naı̈ve Bayes label propagation, in which
the sum of the HumanNet linkages to implicated neighbors is used rather than
their count [59], corresponding to the naı̈ve Bayes estimate for a gene to partici-
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Figure 2.3: Network-linked gene pairs were substantially more likely to show
similar tissue specificity in their expression patterns. This was measured as the
likelihood of co-occurrence of transcripts of pairs of genes in the same tissues across
30 different human tissues from the TiGER database of tissue-specific gene expres-





Figure 2.4: A schematic figure of network-guided prioritization of candidate dis-
ease genes. Given some known disease genes (black nodes), additional genes can
be predicted by their (weighted) associations in the network, with more strongly
connected genes being prioritized more highly (node shading).
pate in the same process as the known disease genes. We further considered four
methods that diffuse disease associations across the network, considering both di-
rect and indirect connections, similar to the methods considered in [77]. Two of
these are mathematically related to Googles PageRank algorithm: (3) the Iterative
Ranking method, in which a genes score is calculated from an initial score and the
normalized scores of its neighbors, which, when updated over successive itera-
tions, smear across the network linkages [74, 78], and (4) Gaussian field label prop-
agation (Gaussian smoothing, for short), in which the difference between a genes
initial and final scores and the weighted score difference between a gene and its
neighbors are simultaneously minimized [73]. Finally, we considered (5) a cluster-
ing approach, using Markov clustering of genes based on simulation of stochastic
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flow in the network [79], followed by ranking of each gene within a cluster for rele-
vance by considering the sum of the genes edge-weights within the cluster relative
to all of its edge- weights [74], and (6) a model based on electrical circuits [80], in
which network edge weights are considered to be analogous to electrical conduc-
tance and disease implicated proteins are considered as ground nodes; candidate
nodes are identified by modelling the application of current to the resulting circuit
and measuring which nodes have the highest modelled current flow.
Figure 2.5 shows examples of ROC curves associating genes with several
human diseases using the Iterative Ranking approach, showing high predictability
for these cases. In order to systematically test if such predictability was common,
and in order to judge the relative merits of the network diffusion approaches, we
next evaluated a more comprehensive set of mouse phenotypes and human dis-
eases.
We first evaluated the predictive power of HumanNet for genes associated
(via orthology) with mouse mutational phenotypes, drawing upon the nearly 4,000
well annotated gene-phenotype associations identified in gene knock-out, gene
trapping, and chemical mutagenesis experiments, and catalogued in the Mouse
Genome Database (MGD) database [81]. In order to minimize the risk of circular
predictions, we performed the tests using a version of the network lacking human
literature-based linkages (i.e., no linkages by HS-CC or HS-LC). For each of the six
approaches, we measured the network predictability for these mouse phenotypes
using cross- validated ROC curve analysis, plotting the distributions of AUC (area





Figure 2.5: Known genes associated with several human diseases are well pre-
dicted by the Iterative Ranking method for propagating disease labels across
HumanNet, as measured using cross-validated ROC analysis. The performance
can be summarized as the area under the ROC curve (AUC), ranging from 0.5 (ran-
dom) to 1.0 (perfect).
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in Figure 2.6. HumanNet shows broad predictive ability of genes associated with
specific mouse phenotypes, and is significantly better than expected by chance us-
ing each of the six algorithms. However, the closely related Gaussian smoothing
and Iterative Ranking approaches perform comparably to each other, and signifi-
cantly better than the other four approaches, indicating that there is a clear benefit
to considering indirect connections as well as direct network connections.
Unlike mouse phenotypes, annotations for human disease genes are still
extremely limited, spanning approximately 3,000 gene-disease linkages in human
versus nearly 100,000 in mouse [11]. From annotations available at The Mendelian
Inheritance in Man (OMIM) database, we selected 263 diseases with at least 3 asso-
ciated genes. We tested the networks ability to associate genes with each of the 263
diseases using cross-validated ROC analysis, testing each of the six approaches,
just as we did for mouse phenotypes (and again, using the version of the network
lacking human literature-based linkages in order to avoid any potential circular-
ity). We observed strong predictability for the human genetic diseases, with many
disease gene sets predicted to high accuracy based upon gene-gene associations in
the network (Figure 2.7). Again, the Iterative Ranking and Gaussian smoothing
approaches performed similarly well, and significantly better than the other four
approaches, confirming the general applicability of network label propagation for





Figure 2.6: Network GBA predictability of genes associated with 3,374 trans-
genic mouse phenotypes. Bar-and-whiskers plots summarize the predictive per-
formance (measured as cross-validated AUC) for each of six algorithms for using
HumanNet to prioritize candidate disease genes. The Iterative Ranking and Gaus-
sian smoothing approaches outperform the others by a significant margin, and
show generally high predictability for more than three-quarters of the phenotypes
tested. In bar-and-whiskers plots, the central horizontal line in the box indicates
the median AUC and the boundaries of the box indicate the first and third quar-
tiles of the AUC distribution, whiskers indicate the 10th and 90th percentiles, and






Figure 2.7: Network GBA predictability of human diseases. A related analysis
to the one shown in Figure 2.6, but of human disease genes, assembled for 268
diseases from the OMIM database, shows similarly strong prediction strengths and
the same relative ranking of algorithm performance.
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Data from diverse sources is used to predict disease genes
We further investigated how the various data sets derived from high-throughput
experiments and model organisms contribute to the mouse and human phenotype
predictions. We examined predictions made by direct network connections using
the naı̈ve Bayes analysis and excluding the human literature-derived HS-LC and
HS-CC datasets as for analysis in Figure 2.6 and 2.7. These contributions are vi-
sualized for the 20 most predictable mouse phenotypes and human diseases in
Figure 2.8. Notably, datasets from worm and fly were strong contributors to the
prediction of mouse phenotypes, as were data from human mRNA co-expression
patterns (Figure 2.8A). Likewise, diverse datasets from yeast were strong contribu-
tors to a variety of well- predicted human diseases (Figure 2.8B). This demonstrates
that most data sets contribute to the predictions, supporting the importance of data
integration for effective disease gene identification.
Combining evidence from network guilt-by-association and genome-wide asso-
ciation studies
Given that network GBA is strongly predictive of human disease genes, a
potentially powerful application of this approach is to combine the network GBA
with the data from GWAS for direct discovery of human disease genes from patient
and control populations. In order to use the information encoded by HumanNet,
our method takes a slightly different approach from the SNP level tests used in the
statistical analysis of GWAS today. Instead of focusing on single SNPs, we try to
identify which genes and pathways might be involved in the disease. There are a
number of reasons for this. First, even the SNPs that are identified in the traditional
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Figure 2.8: The predictive power for loss-of-function phenotypes stems from
a wide variety of data types integrated into HumanNet. Prediction both of (A)
genes associated with mouse phenotypes and (B) of genes associated with human
diseases are supported by diverse lines of evidence, including, for example, fly and
worm data contributing strongly to mouse phenotypes, and yeast data contribut-
ing to human diseases.
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analysis are rarely thought to be the causal variants underlying the disease. This
is due to the fact that the polymorphisms measured by GWAS have been chosen
not for their biological significance, but for being the most informative of the sur-
rounding region of the genome. Second, only a very small fraction of the genetic
heredity of most diseases studied so far can be explained by the SNPs identified
by GWAS [82]. This might be because a very large number of genes are involved
in the diseases, or it might be because rarer variants cause a greater fraction of the
heredity than previously thought [83, 84]. If it is due to the latter, we need to iden-
tify the regions of the genome where these rare mutations are located so that our
search for such variants can be as efficient as possible. Our goal then is to identify
genes and pathways of genes involved in the disease, not the marker SNPs most
strongly correlated with the disease. Third, by taking a gene-centric approach, we
can use the information encoded by HumanNet to improve our predictions. Fi-
nally, by working on the level of genes instead of SNPs, the method generalizes
to future sequencing data, as long as the genetic variation can be associated with
nearby genes.
If a GWAS finds a highly significant gene, it makes sense to attempt to iden-
tify the causal mechanism by which this gene influences the disease by looking at
which pathways proteins encoded by this gene are active in. For example, this
strategy leads to β-catenin expression and WNT signaling as a likely mechanism
by which TCF7L2 influences type 2 diabetes (for review, see Ref. [85]). By per-
forming this type of pathway analysis automatically, it might also be possible to
uncover genes that would not otherwise easily be found. This is especially true
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for genes that fall just under the threshold of significance for the GWAS study,
but which might be “rescued” by considering their interactions with the confident
genes. Recent evidence for the case of human height shows that such minor contri-
butions are common from polymorphisms falling below the significance threshold
for association, but nonetheless contributing to total variation [31].
Unlike the GBA analyses considered above, for GWAS data, definite seed
genes can rarely be found, particularly for the case where the only evidence for
disease association comes from the GWAS itself. In order to make use of the infor-
mation from the genes that are on the verge of being statistically significant, we im-
plemented a “soft category assignment” for the GBA, where only genes that show
a very strong signal are given full weight in the GBA. Notably, the performance of
guilt-by-association in HumanNet is independent of the number of genes linked to
the phenotype, which means that by varying the parameter that assigns weight in
the GBA, we can include successively more genes that are increasingly less likely to
truly be involved in the disease. We chose to base our method on the naı̈ve Bayes
GBA rather than the Iterative Ranking or Gaussian smoothing methods, since naı̈ve
Bayes gave superior recall in the highest precision regime, and the log odds output
of the naı̈ve Bayes can be combined with the log odds from the GWAS in a natural
way.
Let Si denote the total GBA score for a gene i, and denote by pj the proba-
bility that some other gene j is involved in the disease. Suppose that j is connected
in the functional network to i by a link of strength lij. It would then be natural to
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assign a “soft” GBA contribution from gene j to gene i by
∆Si,j =
￿
pj − (1 − pj)
￿
lij,









However, this gives very poor results in practice, most likely because the network is
only built on positive evidence. However, by only keeping positive contributions,







where the sum is only over those j for which 2pj > 1.1
If we assume that the data from the GWAS and the data for the network
are conditionally independent, we can then integrate them in a naı̈ve Bayes frame-
work, which, while not as strongly predictive as the iterative ranking and Gaus-
sian smoothing strategies (Figure 2.4), was nonetheless quite robust for diverse
diseases. The posterior log odds that gene i is involved in the disease are then
ln O (i ∈ D|DN DGWA) = ∑ αjlij + ln O (i ∈ D|DGWA) ,
where ln O (i ∈ D|DGWA) is the log odds of association calculated from the GWAS
data.
1Another natural way to take into account the fact that the network is built only on positive evi-
dence would be to use pj as a weight instead of 2pj − 1. In practice, however, this does not work well
(data not shown).
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Considering network linkages increases the power of genome-wide association
studies
To evaluate whether the genes highlighted by this method actually are genes
that are biologically relevant to diseases we used ROC analysis to compare how
highly the combined GWAS/GBA method ranks the top candidates from meta-
analyses for type 2 diabetes and Crohn’s disease [86, 87], versus how highly those
same genes are ranked by the Wellcome Trust study by itself [4]. These meta-
analyses contain the Wellcome Trust data used for the predictions, but also in-
corporate data from a number of similar size studies, and have higher statistical
power. For both type 2 diabetes and Crohn’s, the Wellcome Trust study considered
about 2,000 cases and 3,000 controls. For Crohn’s, the meta-analysis considered
3,230 cases and 4,829 controls; for diabetes, 4,549 cases and 5,579 controls. To con-
firm that it really is the incorporation of the information encoded by the network
that improves our predictions, we also compared these results with 200 randomly
shuffled networks. As shown in Figures 2.9 and 2.11, the combined GWAS/GBA
method clearly improves the ranking of the genes for both diseases, and does so
over a wide range of parameter settings for the prior parameter.
Genes boosted in Crohn’s
Prior to the Wellcome Trust study, strong association signals for Crohn’s
disease had been observed in NOD2, IL23R, ATG16L1, ZNF365, and in 5q31 and
the gene desert 5p13.1. Furthermore, the Wellcome Trust study identified four
more strong associations that were replicated in follow up studies. These were



























Figure 2.9: Consideration of the human gene network boosts recovery of vali-
dated Crohns disease genes from GWAS analysis of 2000 cases and 3000 con-
trols. The performance improvement achieved by network-boosted GWAS relative
to GWAS alone (Wellcome Trust Baseline, [4]), measuring performance as the area
under a ROC curve up to 5%false positive rate (AUC, < 5%FPR) for recovering
the top 22 Crohns disease genes identified in a larger meta-analysis of 4549 cases
and 5579 controls [86]. For the AUC (< 5% FPR) measure of performance, a per-
fect predictor achieves a score of 0.05, while randompredictors score near 0.00125.
The network boosted approach (colored red line) outperforms the GWAS alone
(straight dashed blue line) over awide range of parameter values. For comparison
we also show the results of network boosting when randomized networks are used,




























Figure 2.10: Network of Crohn’s disease candidate genes (rounded rectangles)
identified from the combination of HumanNet and GWAS data, visualized us-
ing Cytoscape [88]. The node size corresponds to the strength of the combined
evidence from the Wellcome Trust Case Control Consortium (WTCCC) data and
the network, and the intensity of the red color indicates how much the gene was
boosted by the HumanNet GBA. HumanNet linkages are drawn as directed ar-
rows connecting genes, with edge weight scaled by strength of boost contributed
by the source to the sink. All genes are drawn with positive posterior log-odds
when the prior log-odds of association are -1.7, except for network singletons, and
the 50 highest scoring non-singleton genes are shown. Note the strong boost given
to GRB2 and SHC1, which are known to be involved in healing gastric ulcers (Pai et
al. 1999), and to JAK2 and STAT3, which were also identified in later meta-analyses
(Van Limbergen et al. 2009).
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other genes; NKX2-3, and finally, PTPN2. Moderate association was also seen in
the regions 1q24, 5q23, 6p22, 6p21, 6q23, 7q36, 10p15, and 19q13, which contain a
number of plausible candidate genes, such as STAT3 and TNFAIP3.
Using the evaluation method described above, we saw a distinct increase in
the top portion of the ROC curve for a wide range of values for the prior parameter
centered at -1.7 (see Fig. 2.9). Using -1.7 as our value for the prior parameter, we
then surveyed the gene groups that had strong network support. Interestingly,
many of the gene clusters that emerged in this analysis showed strong connections
with TNF-alpha signaling, which suggests multiple points of failure for the TNF-
alpha pathway in Crohn’s disease. We also note that one of the most successful
drugs against Crohn’s disease is the TNF-alpha antibody Infliximab.
IL23R, STAT3, IL12RB2 and JAK2 have all been indicated as candidate genes
for Crohn’s disease, probably affecting the disease through their involvement in the
differentiation of Th17 cells [89]. These are strongly connected in our network, and
therefore boost each other’s rankings. For our choice of the free prior parameter,
STAT3 gets bumped from rank 17 to 7, and JAK2 from rank 3139 to 89. Many of
these are functionally connected in our network to both the adaptor protein GRB2
(rank 99 to 12) and to its interaction partner SHC1 (6125 to 63). GRB2 and SHC1
are also involved in gastric ulcer healing [90]. GRB2 and SHC1 are furthermore
supported by their functional interactions with PTPN2 and MST1, which probably
affect Crohn’s disease via their roles in the orchestration of the secondary immune
response [89]. Lastly, GRB2 is a binding partner to TNFRI, TNF receptor type I
which can mediate a majority of TNF-alpha-dependent activities [91]. All of this
38
taken together indicates that GRB2-SHC1 warrant further study as disease candi-
date genes for Crohn’s disease.
The cluster containing CYLD, TRAIP, and TRAF1 could also show a mecha-
nism of action for Crohn’s disease candidate genes. CYLD is located next to NOD2
on chromosome 16. However, Cyld-/- knockout mice have an IBD phenotype [92],
and CYLD has been shown to interact with TRAIP (TRAF interacting protein) by
yeast two hybrid screens [93]. TRAIP is located in the 3p21 locus, which contains
multiple independent signals for association with Crohn’s disease [94]. Both of
these genes are connected in HumanNet to TRAF1, TNF receptor-associated factor
1, which is involved in TNF signaling and NF-kappaB signaling.
We also see encouraging support of already known loci TNFRSF6B and TN-
FSF15 are both known to be involved in Crohn’s disease, and they are connected
in HumanNet.
Another interesting gene association is given by ATG16L1 and CAPN9, which
boost each other. ATG16L1 is involved in autophagy, and has been implicated in
multiple GWAS. CAPN9 is a stomach specific calpain, and mouse Capn9-/- knock-
outs are sensitive to gastric mucosal injury induced by ethanol administration [95].
This, together with their connection to ATG16L1, indicates that this is another plau-
sible candidate gene for Crohn’s disease.
Genes boosted in type 2 diabetes
Before the Wellcome Trust study, PPARG, KCNJ11 and TCF7L2 had all been
identified as genes involved in type 2 diabetes through genome wide association
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Figure 2.11: Consideration of the human gene network boosts recovery of val-
idated type 2 diabetes genes from GWAS analysis of 2000 patients and 3000
controls. Plotted using the same conventions as in Figure 2.9, analyzing WTCCC
GWAS data [4] for type 2 diabetes alone and in combination with HumanNet and
measuring performance as AUC (< 5% FPR) for recovering the top 20 genes from
a type 2 diabetes meta-analysis of 4549 cases and 5579 controls [87]. As for Crohns
disease, consideration of the network boosts performance across a wide range of
parameter values.
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Figure 2.12: Network of type 2 diabetes candidate genes (rounded rectangles) identified from the
combination of HumanNet and GWAS data. Consideration of the network strongly implicates the
genes CTNNB1 and BACH2 in type 2 diabetes; CTNNB1 is well studied in connection with type
2 diabetes and BACH2 has been previously implicated in type 1 diabetes and celiac disease (e.g.,
[96, 97], but not type 2 diabetes.
studies and replicated in follow up studies (reviewed in [98]). The strongest can-
didate gene for type 2 diabetes, TCF7L2, was also the strongest signal seen in the
Wellcome trust study, although the others were not so strong. However, the ex-
act mechanism by which TCF7L2 acts was not entirely clear. In our analysis, we
find it directly connected to BACH2, a gene that has been repeatedly implicated in
type 1 diabetes (e.g., [96]), but which has not yet been linked to type 2 diabetes.
BACH2 is among the genes most strongly boosted by network linkages, deriving
additional signal from CREB5 and PARD3B, which both score highly in the GWAS
data. PARD6G, PARD3B and CDC42 are also emphasized by the method. Notably,
these genes form a complex with PRKCZ [99], a variant of which correlates with
type 2 diabetes in Han Chinese [100]. EBF1, a known regulator of adipocyte differ-
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entiation [101] is also strongly boosted by the network, supporting a possible role
in type 2 diabetes.
Thus, for both Crohn’s disease and type 2 diabetes, the combined GWAS
/ GBA approach both boosts genes that have support in other populations and
that have been replicated in later meta-analyses, and highlights new connections
between functionally connected genes among the genes that show moderate asso-
ciation to the disease.
2.3 Discussion
A new functional gene network for human genes
In order to test the general ability of a gene network to prioritize disease
genes, particularly in conjunction with GWAS studies, we constructed a genome-
scale functional network of human genes, incorporating diverse expression, pro-
tein interaction, genetic interaction, sequence, literature, and comparative genomics
data, including both data collected directly from human genes as well as that from
orthologous genes of yeast, worm, and fly. The resulting HumanNet gene network
can be accessed through a web interface2. Using this interface, researchers can eas-
ily search the network using a set of seed genes of interest. The interface returns a
list of genes ranked according to their connections to the seed genes, together with
the evidence used to identify each coupling. The interactions and evidence can be
downloaded, and a network visualization tool has been incorporated. All linkages
can also be downloaded for independent analysis.
2Available at http://www.functionalnet.org/humannet.
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Functional networks provide a general strategy for prioritizing disease genes
We demonstrate here that connectivity of human genes in an integrated
functional network is a strong predictor of disease genes, both for cellular phe-
notypes and for diseases at the level of the whole organism. This predictability
is strong even when considering only direct network connections, as shown both
here and by related previous work (e.g., [9, 41, 42, 45]). We further show that algo-
rithms developed originally for predicting gene function using gene networks also
perform well at prioritizing candidate disease genes. Importantly, the considera-
tion of indirect connections in diffusion algorithms, such as Iterative Ranking [78]
and Gaussian smoothing [73]), greatly improves the correct identification of dis-
ease genes. Thus, knowing a few genes implicated in a disease, the networks offer
a strong tool for prioritizing additional likely candidate genes.
One primary limitation of this approach is that genes must already be af-
filiated with the disease in order to predict new candidates. Typically, these seed
genes would come from prior studies. However, we demonstrate that the approach
is still valuable when used in combination with GWAS data, where no genes are
definitively associated with the disease. Recent work also demonstrates that func-
tional networks in worm and yeast can successfully predict genetic modifiers of
genes [60] using the same network guilt-by-association approach. The effective-
ness of this strategy in yeast and worms strongly supports using a human gene net-
work in same manner to predict genes of synthetic or epistatic phenotypes. While
relatively few such genetic interactions are known currently among human genes
[102], as compared to the cases for yeast (e.g., [103–106]) or worm [107, 108], func-
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tional gene networks offer a potential directed strategy for expanding current sets
of human genetic interactions by prioritizing the tested interactions using gene net-
works, and our preliminary results demonstrating prediction of KRAS and OCT4
modifiers (Figure 2.2B) support such an approach.
Tissue specificity profiles are shared by linked genes
One important characteristic of HumanNet is the tendency for linked genes
to share specificity of expression in distinct tissues (Figure 2.3). The observation of
tissue-specificity embedded in networks is consistent with our expectation for co-
localization of proteins in the same functional modules (e.g., protein complexes
and pathways) in specific cell types. However, this is nonetheless notable, since
many of the raw datasets for network construction were not themselves tissue spe-
cific. For example, yeast-two-hybrid (Y2H) interactions are tested not in human
cells but in yeast cells, and in fact, linkages derived only from Y2H do not show
high tissue specificity (data not shown). Similarly, the phylogenetic profiling and
gene neighbor comparative genomics approaches are strictly based on analysis of
genome sequences and make no reference to tissue expression, nor do, for exam-
ple, linkages inferred by homology from yeast. This trend for linked proteins in
a genome-wide functional gene network to share tissue specificity has also been
previously observed for worm and Arabidopsis gene networks [10, 46], and thus
seems to be a result of the training process and integration of multiple data types
correctly capturing the sorts of functional relationships reflected by the tissue speci-
ficity. A practical consequence is that a single genome-wide network of genes is
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nonetheless able to successfully implicate genes in tissue- and cell-type specific dis-
orders, as, for example, the case of liver cirrhosis genes, which are well predicted
(AUC = 0.88; Figure 2.5).
Network-aided association studies: A general strategy for prioritizing genome-
wide associations in human disease
The success of our approach suggests that analysis of GWAS data sets us-
ing gene networks offers a useful strategy for identifying both directly causal genes
and even potential modifier loci in human disease, and since neither the pathway
information encoded by the network nor the disease-association likelihoods that
come out of the GWAS make any prior assumptions about the disease studied,
this strategy is free from the study design bias that is inherent in candidate gene
or candidate pathway analyses. The altered prioritization offered by the network-
based association approach has the effect of shifting attention for follow-up studies
to those genes (not SNPs) that are both best supported independently, and most
likely to impinge upon the process(es) that are themselves best supported by the
GWAS data, as determined from the current state of biological knowledge that has
been objectively reconstructed and summarized in the gene network. Since this
technique is gene focused and not SNP focused, it can be used with any future se-
quencing technology as long as the genetic variations can be associated with genes.
In our analyses of Crohn’s disease and type 2 diabetes, the network boosted iden-
tification of correct associations by 10% (measured in area under the first 5% of the
ROC curve), which translated in practice to one to two genes more for these cases,
a statistically significant, but not large effect. However, the organization of the
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associated genes into processes offered a large practical benefit, such as focusing
attention to BACH2, CTNNB1, and EBF1, which were not well-supported by the
type 2 diabetes GWAS, but which were prominent network connectors between
the well-supported genes. Furthermore, this boost is an effect of using the full
network; individual sources of data do not provide nearly the same coverage and
accuracy as the integrated network, and the kinds of data that is informative varies
for the two different diseases studied (data not shown).
A second overall strategy also presents itself for integrating GBA and GWAS
data sets, that of a candidate gene-based approach: It seems quite feasible to use
GBA to known causal genes in order to select additional candidates, then to evalu-
ate those candidate genes in a directed fashion, either by interrogating the GWAS
data for associations involving these loci, or by directed sequencing of the candi-
date genes in patient populations. By focusing only on those genes ranked highly
by GBA, the multiple testing explosion of typical GWAS is eased considerably, al-
lowing for smaller patient samples to be tested and easier statistical significance
thresholds to meet.
Concluding remarks
In summary, the approach outlined here provides a general method for
prioritizing human disease genes, both for the case where seed genes associated
with the disease are known already, and for the case where no such seed genes are
known, but GWAS data for the disease is available. Our results suggest that the
network will be useful for a considerable fraction of human diseases with genetic
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components, and thus provides a general resource for diverse genetic diseases.
2.4 Methods
Construction of HumanNet
This study is based on 18,714 human Entrez genes with validated coding
proteins (downloaded from NCBI; March 2007). Gene functional associations were
trained using a reference set of gene pairs sharing Gene Ontology (GO) biological
process annotations (downloaded from NCBI; March 2007). We used only annota-
tions supported by experimental evidence: IDA (inferred from direct assay); IMP
(inferred from mutant phenotype); IPI (inferred from protein interaction); IGI (in-
ferred from genetic interaction); and TAS (traceable author statement). To minimize
training bias, we excluded highly overrepresented annotations: (1) signal transduc-
tion (GO:0007165) (this term alone would otherwise account for 38% of total pos-
itive reference gene pairs); (2) three additional phosphorylation terms that have
highly diverse biological roles, protein amino acid phosphorylation (GO:0006468),
protein amino acid autophosphorylation (GO:0046777), and protein amino acid de-
phosphorylation (GO:0006470); and (3) all terms at the first and second levels of the
GO hierarchy (assuming the term biological process is level zero). The resulting
dataset of 270,704 reference gene pairs covers 5,369 (29%) human genes.
Functional associations were learned (as described in detail in the Supple-
mental Methods) in a supervised training framework using the log likelihood scor-
ing (LLS) scheme of [10, 46], monitoring overtraining with 0.632 bootstrapping as in
[10]. Gene associations from each separate dataset described below were optimized
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to maximize performance as measured by precision-recall analysis, in accord with
the rationales presented in [10, 46]. Multiple LLS for each gene pair were integrated
using the weighted sum method with linearly decaying weights as in [10].
Analysis of tissue-specificity of network linkages
The similar tissue specificity of linked gene pairs was measured as the like-
lihood of co- occurrence of transcripts of pairs of genes in the same tissues, calcu-







where P(C|N) and P(¬C|N) are probabilities that genes connected by the network
(N) are co-expressed (C) and not co-expressed (¬C) in the same tissue. P(C|R) and
P(¬C|R) represent similar calculations based on randomized networks (R), repeat-
ing calculations for 100 randomized networks. As a reference for tissue- specific
expression, we collected 5,018 tissue-specific genes and their expression profiles
across 30 different human tissues from the TiGER database of tissue-specific gene
expression [75].
Implementation of network guilt-by-association algorithms
The naı̈ve Bayes GBA algorithm was implemented as previously described
[10]. Briefly, a gene score consists of the sum of LLSs to seed genes. For neighbor
counting, the LLS sum is simplified to a count of neighboring seed genes. For
Markov clustering, MCL software was downloaded from www.micans.org/mcl
[109, 110]. We obtained network clusters using the default granularity settings.
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The final score for a gene consists of the sum of the genes maximal coverage scores
to clusters containing seeds. The coverage score is an MCL measure, comprised
of the sum of edge weights from a node to a cluster, with larger edge weights
rewarded. To obtain random scores for a phenotype set, we randomly selected
from the genome a set of seeds of the same size, and performed naı̈ve Bayes GBA
as before.
The following methods were implemented in Matlab: GeneMANIA Gaus-
sian field label propagation (Gaussian smoothing) was implemented as previously
described [73]. Briefly, seeds were assigned initial scores of 1, and all others n/N,
where n is the number of seeds and N is the total number of network genes. We
then solved the system y = (I + L) f , where y is the set of initial scores, L is the
graph Laplacian matrix of the network, and f is the set of final scores. The method
for Iterative Ranking is derived in detail elsewhere [78]. However, rather than it-
eratively computing the final scores, we solved the system y = (I − U) f , where U
is the matrix of network edges weighted by the sum of outgoing edges from each
node. For the circuit based method, we followed the electrical model proposed
previously [80]. Each edge in the network is treated as the conductance between
the connecting nodes. The seed nodes are designated as the ground reference, and
a current is simultaneously applied to all other nodes in the network. Using Kir-
choff Laws, we solved for the voltage for each node. The final score for a node is
the flow, or the nodes total current multiplied by its voltage.
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Integrating the gene network with genome wide association study data
GWAS data came from the Wellcome Trust Case Control Consortium[4].
We selected the additive Bayes factor as a measure of association between SNPs
and diseases, and represent each gene by the strongest association signal within
10 kb from the beginning or end of the gene. The same analysis for different cut-
offs, varying from 0 to 250 kb, did not significantly change the boosting from the
network.
We approximated the probability of a gene being involved in a disease by
assuming that the space of possible hypotheses was limited to the null hypothesis
and the additive hypothesis used for calculating the Bayes factors, and chose the
value for the prior odds by optimizing the area under the first 5% of the area under
the ROC curve. In general, we observed an improvement for prior (log10) odds
ranging from roughly -2.5 to -1, corresponding to approximately 60 to 1,900 associ-
ated genes, respectively. Finally, in testing the effect of normalizing for node degree
in the gene network, we observed a loss of performance, presumably because node
degree does carry information for associating genes with diseases.
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Chapter 3
Prediction of gene-disease associations using
gene-phenotype associations in multiple distantly related
species
This work is adapted from a manuscript we are preparing for submission,
titled “Prediction of gene-disease associations using gene-phenotype associations
in multiple distantly related species”, for which John O. Woods and I are joint first
authors.
In this paper we develop an extension to the initial phenolog idea that Ed-
ward Marcotte and Kris McGary that makes use of multiple phenotypes in many
distant species. John Woods did some initial prototyping for the naı̈ve Bayes scheme.
I saw the parallell to recommender systems, designed the cross-validation scheme
and prototyped the additive integration scheme. John worked out many of the
problems orthology leads to, implemented the final version of the code, and re-
searched the biological examples. John, Edward, and I wrote the paper together.
3.1 Background
Human traits, diseases, and phenotypes may have orthologous properties
in other organisms, and such properties — typically phenotypes — are identifiable
based on orthology of the underlying genes. Such orthologous phenotypes, or phe-
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nologs, can be used to predict novel disease-causing genes; for example, McGary
et al. identified SEC23IP as a neural crest effector, potentially involved in Waar-
denburg syndrome, based on the orthologous phenotype negative gravitropism in
Arabidopsis [11].
Phenologs are a natural extension of the concept of deep homology: as a
bird’s wing and a human hand arose from a common ancestor structure with a
common complement of genes and a similar developmental program[111], so also
might less obviously related phenotypes derive from a common ancestor pheno-
type affiliated with an underlying conserved gene module. For example, certain
mammalian neural crest defects and plant gravitropism share and partly arise from
an ancient, highly conserved vesicle trafficking system.
We set out to improve upon the original phenologs algorithm, with a goal of
ranking candidate genes relevant to specific traits and diseases, by developing an
unsupervised method to search for similar phenotypes. We reasoned that gene –
phenotype association predictions coming from multiply “nearby” (or high sim-
ilarity) phenologs (e.g., 3.1), preferably across multiple species, should provide
more predictive power than those from single phenologs. Candidate genes are
ranked based on both the number and similarity of cognate phenotypes which in-
volve those genes, in turn suggesting a prioritization for wet lab experiments.
We expanded upon the original phenolog study — which included gene –
phenotype data from human, mouse, worm (C. elegans), baker’s yeast, and Ara-
bidopsis thaliana — by adding data from chicken, zebrafish, and even E. coli, as well
as additional human and worm datasets. We show that phenotype data may come
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Figure 3.1: A Venn diagram with predictions for epilepsy based on the 40 most similar
phenotypes, based on the Pearson sample correlation, and using cosine similarity as the
weighting function. The nineteen closest phenotypes are each displayed separately, and
the remaining twenty-one are aggregated into the category “below top-19 phenotypes.”
Paralogs are grouped together when they coincide at a prediction score. Genes in bold
represent the orthogroups used in the search — that is, those groups of orthologous genes
where one or more paralog was already associated with epilepsy in our database.
54
from a variety of sources, including BO biological processes and gene expression
annotations, and that the integration of signal from multiply phenologs markedly
improves the predictive power of the method.
3.2 Results
A key advantage to a neighborhood-based approach for predicting gene –
phenotype associations is the ease with which non-obvious — and thus interesting
— biological stories may be teased out. We demonstrate the process with epilepsy,
a human syndrome; mouse susceptibility to pharmacologically-induced seizures, a re-
lated phenotype, using only E. coli data; and atrial fibrillation, the leading cause of
arrhythmia in humans.
In addition to offering concrete predictions, we compare two classifiers for
integrating phenologs (additive and naı̈ve Bayes), across a variety of similarity or
distance functions, and with different neighborhood (k) cutoffs. We also experi-
ment with changing the weighting function used to assign prediction scores.
We experimented with two different frameworks for translating gene – phe-
notype associations between species, and designed a cross-validation scheme for
each of these frameworks. In order to compare performance predicting pheno-













































































Figure 3.2: The method for calculating phenolog overlaps (or the similarity between two pheno-
types coming from separate species) can bias the results, particularly for those species that are rel-
atively isolated from the rest in the phylogenetic tree (e.g., plants). (a) Hypothetical orthogroups
between some species h and another species m are pictured, considering a phenolog from that pair
of species. The genes to the left of the orthogroup node are orthologous to the genes to the right, and
vice-versa. Those genes indicated in red are associated with the phenolog. Matrices are displayed
for predicting (b) species h using genes as rows, (c) species m using genes as rows, and (d) either
species h or species m symmetrically using orthogroups as rows. In (b-d), bullets indicate an associa-
tion between the gene and the phenotype φi. These matrix configurations produce radically different
similarity scores using the hypergeometric CDF; only the orthogroup method produces scores that
do not depend on the direction of the prediction.
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Comparing genes between species
We tested two different frameworks for translating gene queries between
species. For “gene-based” searching: given gene – phenotype interactions from a
number of species, we encode the associations in matrices ΦS, for S ∈ {human,






1 if any ortholog in S of gene i
is associated with phenotype j,
0 otherwise,
where we used the INPARANOID algorithm [112] to approximate which genes in
different organisms are orthologs of each other.
The INPARANOID algorithm discovers orthology relationships in the form
of orthogroups (3.2A). For the method above we simply translate other species’
gene – phenotype associations into the human gene – phenotype matrix by or-
thogroup, and compare the phenotype columns in terms of human genes (3.2).
This scheme works well for closely-related species, where translations are 1:1 (e.g.,
a human gene has exactly one orthologous mouse gene).
However, when attempting to predict Arabidopsis phenotypes, we noticed
that the translation process resulted in unusual scores, particularly when large or-
thogroups were involved (3.2). The genes-as-rows configuration also inflated per-
formance, as measured by ROC plots, during cross-validation — primarily due to
the high frequency with which plant gene expansions co-participate in a biological
process.
Consequently, we began using an “orthogroup-based” matrix configura-
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1 if any gene in the orthogroup i
is associated with phenotype j,
0 otherwise.
The orthogroup-based matrix has the advantage of producing consistent, symmet-
ric similarity scores irrespective of the direction of prediction; furthermore, these
scores are not inflated by the presence of multiple phenotype observations in a
single orthogroup.
Integration methods
Our goal is to construct a set of predictions for gene-phenotype associations
X such that Xij is higher for pairs where the gene is actually associated with the
phenotype.
One way to incorporate information from multiple phenotypes is by mea-
suring some kind of distance between pairs of phenotypes, and integrating the
information from different phenotypes in such a way that “closer” phenotypes get
more weight than phenotypes “far away”. We tested two different ways of inte-
grating this information — one multiplicative naı̈ve Bayes scheme, and one addi-
tive method.
The naı̈ve Bayes scheme we use was first described in the original phenolog
paper [11], and can be written as follows:










fijl = P(gene i ∈ disease j|phenotypes j and l are phenologs) (3.2)
wjl = P(phenotypes j and l are phenologs) (3.3)
As a proxy for the weighting function wjl we have tried a wide range of measures
that calculate a similarity or distance between two sets. Pearson sample correlation
is a particularly popular option for expert recommendation systems. McGary et al.
used the hypergeometric CDF, which gives the probability of seeing an overlap of
size v or greater between phenotypes of size m and n, with N total orthogroups in
the species pair.
For fijl we use v/n, the fraction of the number of genes common to both
phenotypes j and l over the number of genes known to be involved in phenotype
j, which empirically appears to be a good approximation for the probability that a
candidate gene from a single phenolog will turn out to be a true positive.
We also developed an additive classifier. Whereas the naı̈ve Bayes method
multiplies distances or similarities as if they were probabilities, for the additive
method we calculate Xij for each gene-phenotype pair (i, j) by taking the sum over
all phenotypes l, weighted by the similarity between j and the phenotype l, so
Xij = ∑
k
wjkΦik = (ΦwT)ij, (3.4)













































Phenotypes (ordered by best median rank)B
Figure 3.3: Effect of distance measure choice for ordering and weighting. Here
we plot for how many diseases the median rank of the gene withheld during cross-
validation stays at a certain level, using all available species, and integrating the
results using the naı̈ve Bayes scheme. In A, we vary the distance and weighting
function (using the same measure for both). In B, we show the effect of varying
the distance function independently from the weighting function. Here the first
function in the legend is the distance function used for computing the k nearest
neighbors, and the second is the weighting function wij from 3.1 and 3.4. As can be
seen from the figure, a good distance function has more effect on performance than
a good weighting function, but that the results can be improved slightly by using a
combination: hypergeometric for distance, and Pearson for integration.
In addition to hypergeometric CDF and Pearson sample correlation, we
tested Euclidean distance, taxicab (Manhattan) distance, cosine distance and Tan-
imoto coefficient as similarity measures, both for finding the k nearest neighbors
and as weighting functions. Euclidean and Manhattan distance performed ex-
tremely poorly in five-fold cross-validation, so we excluded them from analyses in
the orthogroup framework. Overall, Pearson and hypergeometric appear to have
the most power for identifying nearby predictive phenologs (Figure 3.3A).
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We also repeated the analysis while varying the distance function (used for
searching) and holding the recommendation function (w) the same, and vice-versa
(3.3B). Pearson sample correlation showed the best performance of the distance
functions; however, we found that the hypergeometric CDF was the best weighting
function for assigning prediction scores to genes.
We compared the naı̈ve Bayes and additive classifiers, with the results shown
in Figure 3.4. The performance in cross-validation is quite similar between the two
classifiers, with the best version of the naı̈ve Bayes classifier (using Pearson cor-
relation for distance and hypergeometric for weighting) performing slightly better
than the best additive one (using Pearson correlation and hypergeometric similar-
ity). However, the additive classifier allows us to visualize and deconstruct the
prediction into component phenotypes. We therefore chose to use the additive
classifier for most predictions.
Varying the number of neighbors used (k) tended to affect lower-ordered
predictions (e.g., the thousandth gene predicted for a disease) to a larger extent
than top predictions. Figure 3.10 shows that even including the k = 5 nearest
neighbors improves the results modestly — raising the number of diseases for
which the withheld genes can be predicted at a top-100 median rank from around
50 to 80. Searching for the k = 40 nearest neighbors seems to offer no meaningful
improvement over k = 10, unless one is interested in testing a thousand or so pre-
dictions; higher k values seem primarily to include withheld genes at lower median
ranks.
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Phenotypes (ordered by best median rank)
Figure 3.4: Orthogroup-based matrix predictiveness. Here we show a comparison
of naı̈ve Bayes and additive classifier predictions, which seem to have similar per-
formance, using leave-one-out cross-validation. As in figure 3.3B, the first function
in the legend is the distance function used for computing the k nearest neighbors,
and the second is the weighting function wij from 3.1 and 3.4.
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turned out to be combinations of diseases that were accidentally binned together in
the initial version of our OMIM database (such as achromatopsia and achondropla-
sia). Blood type was one unpredictable — but properly binned — phenotype, likely
due to the discrete nature of genes involved. In other words, each component of
blood type (A and B, positive and negative) should be viewed as an independent
monogenic phenotype.
The best similarity functions produced highly correlated predictions. Fur-
ther, the best predictions of the worst classifiers were highly correlated with the
best predictions of the top-performing classifiers. We thus concluded that the po-
tential benefits of a fusion classifier would be modest at best, and difficult to mea-
sure at worst.
While similarity functions produced remarkably similar results, predictions
coming from different species were much less strongly correlated (see 3.11). One
potential improvement may be to weight phenotypes by species. While each species
provides uncorrelated prediction information, the human disease predictions are
dominated by mouse whenever that species is included — likely because of the
highly correlated nature of the study of gene – phenotype associations in mouse
and human.
Control: Randomized Matrices
To get an idea of how the scores are distributed when we attempt to pre-
dict from pure noise, we generated a series of random gene-based matrices. For
each phenotype-column of cardinality p, we marked p randomly-drawn genes as
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Figure 3.5: Real vs randomized data. Shown are ROC and precision-recall plots
for k = 100 naı̈ve Bayes using the hypergeometric weighting function, predicting
human (OMIM) gene – disease associations from human, mouse, worm, fruit fly,
yeast, and plant gene – phenotype association data. We restrict the evaluation to
only those phenotypes with four or more known genes. The solid line shows the
actual data, and the dashed line shows the result on similarly sized random gene
sets.
observed. We attempted to predict phenotypes-of-interest from these randomized
matrices using our regular classifiers (Figure 3.5 bottom).
As a random gene-based matrix would lack the structure which previously
caused us to switch to orthogroup-based matrices — multiple paralogs partici-
pating in the same phenotype — we judged it unnecessary to randomize the or-
thogroup matrices.
Epilepsy
We chose epilepsy from our list of diseases because, despite offering osten-
sibly correct predictions, it actually scores somewhat poorly in cross-validation. In
64





PAX6 · PRRX1 · RAX2
PAX3 · PAX7 · NKX2-1 · HESX1
ME1 · ME3 · ME2
SLC25A12 · SLC25A13 · SLC25A18 · SLC25A22





Regulation of gene expression by genetic imprinting (At)
Abnormal brain wave pattern (Mm)
Cotyledon development (At)
Aldicarb hypersensitive (Ce)
Hypoosmotic shock hypersensitive (Ce)
Body levamisole resistant (Ce)
Acetylcholinesterase inhibitor resistant (Ce)
Trichlormethine (Sc)
Fatty acid biosynthetic process (At)
Epidermal cell differentiation (At)
Anthocyanin accum. in tissues in response to UV light (At)
Pentose-phosphate shunt, oxidative branch (At)
Papuamide (Sc)
Malate metabolic process (At)
Gene silencing by RNA (At)
NKX2-8 · NKX2-6 · NKX2-4
Figure 3.6: Epilepsy Each row of this chart represents a set of genes predicted with the same score.
If a row’s label (text) is printed in green, at least one of the genes predicted is already known to
be involved; the other genes are likely to be paralogs. Rows with black-text labels are novel pre-
dictions. The depicted search makes predictions based on the k = 40 nearest neighbor phenotypes
(from human, mouse, chicken, zebrafish, worm, yeast, and plant), and color codes the nineteen near-
est neighbor phenotypes’ contributions to each prediction (the remaining twenty-one are grouped in
blue, as “below top-19 phenotypes”). The top scoring gene, ARX, is predicted primarily by Proud
syndrome, hydranencephaly, and Partington’s syndrome, all of which are human diseases character-
ized partially by seizures; but information is also drawn from a variety of plant phenotypes. These
predictions were generated using an additive classifier for ease of visualization. The distance func-
tion is Pearson sample correlation, using cosine similarity as the weighting function w.
our initial three-fold leave-one-out test, only one of the three separately withheld
genes was recovered at a reasonably testable rank (twelve, in this case).
Our method successfully identifies GABBR1, GABBR2 [113], and KCNA1
[114], which were absent from our database but known to be associated with the
disorder. These were predicted primarily due to mouse phenotypes that resemble
epilepsy (clonic seizures and abnormal brain wave pattern; see 3.1 and 3.6).
Top epilepsy predictions include PAX6, PRRX1, and RAX2 (of which PAX6
has been associated with seizures); and PAX3, PAX7, HESX1, and NKX2-1, NKX2-4,
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NKX2-6, and NKX2-8 (3.6)). Notably, NKX2-1 is involved in mouse epilepsy [115],
and PAX3 appears in a region linked to the human version of the disease [116]);
neither of these genes were in our database.
Interestingly, these predictions come from the Arabidopsis phenotypes reg-
ulation of gene expression by genetic imprinting, cotyledon development, epidermal cell
differentiation, and gene silencing by RNA, as well as the yeast phenotype annotation
for sensitivity to trichlormethine (nitrogen mustard, or tris(2-chloroethyl)amine).
To learn more about the general predictability of the epilepsy phenotype,
we ran an expanded cross-validation, withholding each of the full set of 51 epilepsy
genes in our database, and found that six genes could be predicted back — all
within the top 120 ranks.
We wanted to know the extent to which predictions could be attributed
to paralogy (shared orthogroup membership) with genes already associated in our
database with epilepsy. GABBR1 and GABBR2 are each singleton orthogroup mem-
bers, and are thus independently predicted. KCNA1 and KCNA2 emerged as par-
alogs following the human – worm divergence, but are predicted from non-worm
phenotypes — and are therefore also independent predictions.
PAX6’s plant – human paralogs make up the top three rank bins in 3.6.
We suggest that even non-independent predictions are of use, provided they are
accompanied by independent predictions — since, as mentioned, PAX3, NKX2-1,
and PAX6 are all associated to some degree with seizures and/or epilepsy. Indeed,
the inclusion of species in which these genes are not paralogs offers additional
resolution on predictions and demonstrates the utility of our method.
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Figure 3.7: Mouse seizures from E. coli These mouse phenotype predictions are con-
structed from the k = 10 nearest neighbor E. coli phenotypes, using no other species. Pre-
dicting a eukaryote from a prokaryote is low-resolution, due firstly to evolutionary expan-
sions of ancestral orthologs into larger orthogroups, and secondly to the tendency for some
orthologs to vanish from certain species or become unrecognizable. Nevertheless, the prob-
ability of seeing an intersection of six or more orthogroups by chance, such as that between
tobramycin-0.05-unspecified and the seizure phenotype, is 1.7 × 10−4 (without correction for
multiple testing).
Predicting from E. coli — Pharmacologically-induced Seizures
We selected “pharmacologically-induced seizures” because this mouse phe-
notype could be predicted extraordinarily well from E. coli alone in cross-validation:
eight of the forty-eight genes associated with this mouse phenotype could be pre-
dicted back when withheld.
These results are particularly impressive because they represent all six of
the mouse – E. coli orthogroups associated with this seizure phenotype. Two of the
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orthogroups (Grik2/Grik5 and Slc1a2/Slc1a3) are in the top prediction ranking bin;
additionally, Faim2 is in the top hundred ranks (3.7).
The predicted gene α-adducin, likely the most promising result, is known to
be reduced in the brains of rats experiencing kainate-induced seizures [117].
Another interesting prediction is Sv2a (synaptic vesicle glycoprotein). It was
recently reported that a mutation in chicken SV2A leads to photosensitive reflex
epilepsy [118]. Mouse Sv2a is a known binding site for levetiracetam, an antiepilep-
tic drug [119], and Sv2a−/− mice experience seizures and die within three weeks of
birth [120, 121].
We also searched for the source E. coli phenotypes (which happened to be
chemicals) to see if these were associated with seizures. Standouts are ethanol —
alcohol poisoning and alcohol withdrawal symptoms include seizures — as well
as paraquat, which causes seizures and brain damage in rats [122], and aztreonam,
which is a convulsant [123]. While nearly any compound is likely to lead to seizures
if given in sufficient amounts, a back-of-the-envelope PubMed search for ten ran-
domly chosen E. coli phenotypes from our database failed to turn up such clear
associations.
Atrial Fibrillation
We selected atrial fibrillation (AF) for study because it had performed well
in cross-validation in the gene – row configuration method. However, in the ortho-
group-based cross-validation, only three of the eight genes associated could be pre-
dicted after being withheld. The removed genes were predicted at ranks 3–4, 15–16,
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small scala media (Mm)
achlorhydria (Mm)
increased circulating adrenaline level (Mm)
enlarged stomach (Mm)
prolonged QT interval (Mm)
abnormal gastric gland (Mm)
abnormal renin activity (Mm)
detached otolithic membrane (Mm)
absent vestibular hair cell stereocilia (Mm)
mitral valve stenosis (Mm)
pulmonary hypertension (Mm)
abnormal frontal plane axis (Mm)
Atria at stage 28 (Gg)
abnormal canal morphology (Mm)
Torsades de pointes, drug-associated (3) (Hs)
increased circulating gastrin level (Mm)
hypochlorhydria (Mm)
syndromic hearing impairment (Mm)
abnormal vascular resistance (Mm)
bifid atrial appendage (Mm)
Figure 3.8: Atrial fibrillation These predictions are constructed in the same manner
as those in 3.6. Limiting the search to k = 40 neighbors in this case means that all
predictive phenotypes come from mouse and chicken, though other species were
included in the analysis. Interestingly, few of the informative mouse and chicken
phenotypes are related to the heart in any obvious manner.
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and 81–94.
The top-ranked new prediction for atrial fibrillation (AF) is histamine recep-
tor H2 (HRH2), largely contributed by gastrointestinal phenologs (3.8). Histamine
has been known to act on heart cadence for over a hundred years [124]. However,
an empirical link between heart and gastrointestinal function was established by
the recent observation that histamine increases the heart rate in pythons during di-
gestion [125] — regulation which occurs via the H2 receptor [126–128], and which
is apparently ubiquitous in vertebrates.
Similarly predicted are ATP4A and, further down the list, ATP4B, which are
the α and β subunits of the H+/K+ ATPase. This proton pump is responsible for
gastric acid secretion during digestion.
A somewhat speculative connection is offered by recent work, which showed
cigarette smoke extracts cause an increase in the amount of H+/K+ ATPase in the
stomach [129]. It is unclear — and worth testing — whether ATP4A and ATP4B
are expressed in the heart. These genes could offer an additional route by which
smoking contributes to heart problems.
Following HRH2 and ATP4A is HOPX, or homeodomain only protein x, which
is down-regulated during heart failure in humans [130]. It is not clear that HOPX
is involved in AF per se, but worth exploring.
Next is KCNE1, based on orthologous phenotype prolonged QT interval —
and seemingly also a factor in rare cases of atrial fibrillation [131–133].
GJA1 (gap junction protein, α1, also known as connexin 43 or Cx43) is one of
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the two most abundantly expressed connexins in the heart [134–136]. The other
is GJA5 (connexin 40), already associated in our database with AF. Cx40 and Cx43
seem to form heteromeric channels with different properties from homomeric chan-
nels [137]. Cx43, unlike Cx40, is essential for heart development and cardiac im-
pulse conductance in mice [138]. Tuomi et al. observed that a dominant negative
Cx43 mutant causes severe AF [139]. Finally, atrial fibrillation was observed in a
somatic mutation in human GJA1 [140].
A similar story may be told for SCN5A (human cardiac sodium channel,
voltage-gated, type V, α subunit), which is tied with GJA1. This sodium channel
component has been associated with atrial fibrillation [141–143] but was missing
from our database.
The top AF phenologs can be grouped into three basic categories: cardiac,
gastric, and auditory. We have explored the first two categories, but have not con-
sidered genes from the third. We note that while Jervell and Lange-Nielsen syn-
drome (i.e., long QT syndrome) has been associated with deafness for half a cen-
tury [144–147] via alleles of KCNQ1 [148] and KCNE1 [149], other genes may yet be
involved [150]. Further, Belmont et al. write of “a growing appreciation for condi-
tions that affect hearing and which are accompanied by significant cardiovascular
disorders” [151].
Given the incredible success with which our method was able to predict
atrial fibrillation genes — and with which it was able to identify potentially related
disorders — exploration of additional candidates (e.g., ATP4A/B, POU4F3, and
S1PR2) from 3.8 may be warranted.
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Plant phenotypes — Response to Vernalization
Our search system is also capable of predicting gene – phenotype associa-
tions in species other than human. A number of factors reduce resolution in plant
predictions. Firstly, while human phenotypes are predicted from other mammals
and even other vertebrates — which are phylogenetically similar — there are no
close neighbor species to Arabidopsis in our database.
Secondly, while 19,439 of the 28,002 human genes in our database have or-
thologs in other species, the ratio is less promising for A. thaliana phenolog predic-
tions: 12,668 of 27,325 have orthologs. The cause is likely again the lack of other
plants in our database, compared to the several vertebrates from which to draw
information for H. sapiens.
Third and finally, the Arabidopsis genome contains a great deal of redun-
dancy, as observed in [152]: 37.4% of proteins belong to families of more than five
numbers, compared to 12.1% in fruit fly and 24.0% in worm. In orthology-based
predictions, as with phenologs, there is no way to distinguish between such dupli-
cations — except perhaps by relying on paralogous phenotypes.
We determine phenotypes which may be predictable by cross-validating
predictions produced from all non-plant species in the database (3.12). We make
final predictions for response to vernalization (shown in Fig. 3.9).
We selected this phenotype because it scores better than most other plant
phenotypes in cross-validation; seven of the fifteen genes in this plant phenotype
can be predicted back at low rank when withheld, representing two or three or-
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SVP · MAF4 · MAF1 · FLC · MAF3 · MAF5
SEP4 · AGL6 · SEP2 · AGL79 · AGL13 · AGL14 · AGL21 · AGL15
SEP1 · TT16 · AT5G51860 · AGL8 · AGL42 · SEP3 · CAL · AP1
AP3 · PI · GOA · AGL12
AGL44 · AGL17 · AGL16 · AGL18 · AGL24 · AGL71
SHP2 · AGL20 · SHP1 · STK · AG · AGL19
AGL30 · AGL65 · AGL94
FWA
HDG7 · HDG11
HDG3 · HDG1 · PDF2 · ANL2 · ATML1 · HDG12 · HDG2
HDG8 · HDG9 · HDG10
HDG4 · AT5G07260 · HB-7
below top-20 phenotypes
GO:0048701:embryonic cranial skeleton morphogenesis (Dr)
Neural Plate/Tube at stage 44 (Gg)
abnormal endocardium morphology (Mm)
Epiblast at stage 2 (Gg)
Kohler's Sickle (Gg)
Ectoderm at stage 4 (Gg)
abnormal branchial arch artery morphology (Mm)
GO:0010221:negative regulation of vernalization response (At)
GO:0050936:xanthophore differentiation (Dr)
GO:0030241:skeletal muscle myosin thick filament assembly (Dr)
GO:0021782:glial cell development (Dr)
GO:0010628:positive regulation of gene expression (Dr)
dilated dorsal aorta (Mm)
abnormal sinus venosus (Mm)
GO:0006349:regulation of gene expression by genetic imprinting (At)
GO:0009910:negative regulation of flower development (At)
abnormal sinoatrial node morphology (Mm)
Figure 3.9: Arabidopsis vernalization Here, we demonstrate predictions for a
plant phenotype, response to vernalization, while also demonstrating how includ-
ing paralogous phenotypes may slightly enhance resolution. These predictions are
drawn from phenotype data from each species in the database, with a neighbor-
hood cutoff of k = 40. Due to the large gene expansions in plants, as well as the
relatively large distance of Arabidopsis from other species in our database, paralogs
are often ranked together. In the first two bins, a large gene expansion is split into
separate ranks by information from an Arabidopsis phenotype (which is paralogous
rather than orthologous). Those ranks labeled with green text include at least one
previously known vernalization response gene (that is, a gene that was already
linked with vernalization response in our database).
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thogroups (about half of the total number of orthogroups) depending upon the
source species considered.
Although we cannot cross-validate predictions from paralogous phenotypes,
since they are not sufficiently independent, we feel that the inclusion of paralogous
phenotype data improves the resolution at no perceivable cost.
Owing to the slow pace of study of plant genes, it is difficult to determine
whether predicted genes (3.9) are correctly implicated.
However, we note at least two interesting predictions. One of these, EMF2
— which appears to be associated with vernalization-mediated flowering by its in-
teraction with CLF [153] — is predicted based on seemingly unrelated orthologous
mouse and human phenotypes (abnormal chorion morphology and endometrial
cancer, respectively).
EMF2 is paralogous with known vernalization gene VRN2; however, it is
ranked ahead of VRN2 by its association with the related plant phenotype negative
regulation of flower development. That EMF2 was boosted by a potential paralogous
phenotype supports the hypothesis that paralogous phenotypes are similarly use-
ful to orthologous phenotypes in predicting gene function.
The second interesting prediction is FWA and its several paralogs (HDG1–4,
HDG7–12, PDF2, ANL2, ATML1, AT5G07260, and HB-7).
Certain FWA mutants produce a vernalization-insensitivity phenotype [154,
155]. Candidates ANL2 and PDF2 both have late flowering phenotypes [156, 157]
markedly similar to that of FWA [158]. That discovery lends additional support for
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paralogous phenotypes, as neither FWA nor PDF2 were associated in our database
with regulation of flower development — but our method successfully identified
negative regulation of flower development as a potential phenolog.
Fruit Fly Phenotypes
While FlyBase holds a wealth of knowledge on gene – phenotype associa-
tions, we found it difficult to leverage for our goals. The controlled vocabulary is
designed for searching for classes of phenotypes rather than the phenotypes them-
selves.
Unfortunately, the only way to connect a phenotypic class annotation to an
anatomical location or developmental stage is by allele and literature reference — if
these are given at all. While it was possible to predict some human diseases based
on fruit fly phenotypes from FlyBase, the results were difficult to interpret.
Given the resulting noisiness and sheer quantity of data, we anticipated
that correct predictions would be attributable to multiple hypothesis testing, and
chose to exclude fruit fly results.
Pharmogenomics Knowledge Base Phenotypes
The Pharmacogenomics Knowledge Base, PharmGKB, offers a wealth of
gene – phenotype associations. However, these associations are typically made by
way of a drug used to treat a disease — which may act on a target which is not
directly involved in the disease.
While we chose not to include PharmGKB results, the data is available
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alongside the source code.
3.3 Conclusion
We set out to improve upon the results of the original phenolog project
by unifying information from a “neighborhood” of phenotypes surrounding the
desired disease. Our method produces ranked predictions for a large percentage of
human diseases in OMIM, as well as for plant biological process-based phenotypes.
Furthermore, we were able to demonstrate the correct prediction of at least
one gene associated with the mouse phenotype pharmacologically-induced seizures
using only phenologs from E. coli. While McGary et al. demonstrated the existence
of deep homology between mice and single-celled eukaryotes, our work suggests
that examples of deep homology exist — and may even offer useful predictions —
between prokaryotes and eukaryotes.
We also demonstrate that the term “phenotype” may be interpreted broadly
when incorporating gene-association data for phenolog-based predictions. Gene
Ontology biological processes are one potential source; another is annotations for
in situ hybridization experiments, such as GEISHA.
We give a number of concrete gene predictions for the human diseases atrial
fibrillation and epilepsy, and show how phenologs may be used to generate hy-
potheses and a biological context that correctly connect categories of diseases, such




For the gene-based matrix, we compared classifiers and metrics using n-
fold cross-validation, and calculated receiver-operating characteristic (ROC) and
precision–recall curves for each disease or phenotype to be predicted. Classifiers
could be represented by arrays of area-under-the-curve measurements.
With the orthogroup-based matrix we chose a simpler and faster “leave one
out” cross-validation scheme, where one observed gene association was hidden for
each disease. Noting that some orthogroups have multiple genes associated with
the same phenotype, we also hid any orthogroups associated with hidden genes.
Since a gene may be part of one orthogroup for each species included in the search,
we measured the rank of predicted genes rather than predicted orthogroups. When
multiple genes were predicted with the same score, the mean rank was used.
The leave-one-out procedure was repeated three times for each phenotype,
taking the median hidden gene rank to be representative of the classifier – pheno-
type performance.
Additional phenotype data
In addition to those databases described in [11], we incorporated orthology
and gene – phenotype data from a variety of additional species.
New C. elegans phenotypes came from Green et al. [159] and were broken
down into two datasets: green-broad and green-specific.
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We added, without modification or filtering, a second human dataset (phar-
mgkb) from the Pharmacogenomics Knowledge Base [160].
E. coli phenotypes were taken on May 20, 2011, from the file ‘coli FinalData2.txt’
[161]. Each gene’s phenomic profile was sorted by score, assigning both the top and
bottom forty conditions to the gene. Thus, each condition was considered to be a
phenotype, and the genes associated with that phenotype were those genes whose
growth was most affected — either positively or negatively — in the corresponding
condition.
Fruit fly phenotypes came from FlyBase [162]. We attempted to match
anatomical annotations for mutant phenotypes to annotations from the phenotypic
class ontology, joining on allele and publication.
Zebrafish phenotypes consisted of gene ontology (GO) biological processes
from ZFIN [163], keeping only those annotations with evidence types of IMP, IDA,
IPI, IGI, TAS, NAS, IC, and IEP — the same procedure used for Arabidopsis phe-
notypes, obtained from TAIR [164]. These evidence types were selected so as to
avoid the inclusion of annotations that originated directly from knowledge of other
model organisms.
For chicken (Gallus gallus) phenotypes, we utilized in situ hybridization an-
notations from GEISHA [165], kindly provided in XML format on June 24, 2011. If
there were more than fifty genes associated with a specific location and more than
three at a specific state at that location, a new phenotype was created (“anatomical




















Phenotypes (ordered by best median rank)
Figure 3.10: Effect of k on Predictiveness. We compare different k-values in the
neighborhood search for phenologs. This graphic demonstrates the effect (and di-
minishing returns) of increasing k on recovery of withheld genes.
We defined phenotypes as gene – expression associations in specific anatom-
ical locations. For those locations with more than fifty genes annotated, we created
additional phenotypes for each stage with greater than three associated genes.
While developing the orthogroup-based matrix configuration, we updated
our human OMIM dataset. Thus, predictions from that implementation utilized a
somewhat different database than those used by McGary et al.
















Figure 3.11: Contributions by Individual Species. A demonstrates that each phe-
notype offers some sort of information for prediction of human disease genes;
mouse data seem to offer the most information about human diseases, as one
would expect from the quality of the data and the proximity of the species in the
phylogenetic tree. Arabidopsis, which is the furthest species from human in our
database, unexpectedly provides as much information as mouse on top predic-
tions, and is second at higher ranks. B A scatter plot qhich demonstrates that the
information offered by each species (in this case mouse and Arabidopsis is highly
independent, and suggests that integrating data from multiple species may be use-
ful.
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Figure 3.12: Predicting Plant Phenotypes. This figure mirrors 3.11A, but demon-
strates the prediction of Arabidopsis phenotypes from individual species (rather
than human diseases from individual species). The red solid line shows the com-
bined performance of predictions using all species except Arabidopsis. Yeast ap-
pears to be the most useful individual species for predicting plant phenotypes.
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Chapter 4
Prediction and validation of gene-disease associations using
network methods
This part grew out of collaborative filtering inspired work in the previ-
ous chapter, and was done in collaboration with Nagarajan Natarajan in Inderjit
Dhillon’s lab, and Ambuj Tewari (formerly in Dhillon’s lab, now a professor at
University of Michigan in Ann Arbor).
Nagarajan and I have worked very closely on this project, and bounced
ideas back and forth. The idea for the support vector machine formalism came
from Naga and Ambuj, while I have done the analysis of the results.
4.1 Abstract
Correctly identifying associations of genes and diseases has long been a
goal in biology. With the emergence of large-scale gene-phenotype association
datasets in biology, we can leverage statistical and machine learning methods to
help us achieve this goal. In this paper, we present two methods for predicting
gene-disease associations based on functional gene associations and gene-phenotype
associations in model organisms. The first method, Katz, is motivated from its suc-
cess in social network link prediction, and is very closely related to some of the re-
cent methods proposed for gene-disease association inference. The second method,
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called CATAPULT(Combining dATa Across species using Positive-Unlabeled Learn-
ing Techniques), is a supervised machine learning method that uses a biased sup-
port vector machine where the features are derived from walks in a heterogeneous
gene-trait network. We study the performance of the proposed methods and re-
lated state-of-the-art methods using two different evaluation strategies, on two
distinct data sets, namely OMIM phenotypes and drug-target interactions. We
also present qualitative analysis of predictions made by the methods and demon-
strate that using one of our two evaluation strategies based on singleton traits yields
performance comparisons that match how the predictions made by the respective
methods compare qualitatively.
4.2 Introduction
Correctly predicting new gene-disease associations has long been an im-
portant goal in computational biology. One very successful strategy has been the
so-called guilt-by-association (GBA) approach, in which new candidate genes are
found through their association with genes already known to be involved in the
condition studied. This association can in practice be derived from many different
types of data. Goh et al.[166] construct a network where genes are connected if
they are associated with the same disease, whereas Tian et al.[167] combine protein
interactions, genetic interactions, and gene expression correlation, and Ulitsky and
Shamir[168] combine interactions from published networks and yeast two-hybrid
experiments.
One of the most commonly used kinds of association is derived from di-
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rect protein-protein interactions, such as the ones curated by the Human Reference
Protein Database (HPRD) [169]. The last few years have seen a number of methods
that have extended the association from just direct protein interactions to more dis-
tant connections in various ways, such as CIPHER [170], GeneWalker [171], Prince
[172] and RWRH [173]. One kind of network that has proven to be particularly use-
ful for predicting biological function is the functional interaction network, where a
pair of genes is connected based on the integrated evidence from a wide array of in-
formation sources, as seen in Lee at al.[8]. These have been used to associate genes
with phenotypes in model organisms [9, 73] and in humans [44, 45]. A recently
published network, HumanNet, has been used to refine predictions from genome-
wide association studies [21]. Since functional gene interaction networks aggregate
many different types of information, they can achieve much greater coverage than
pure protein-protein interaction networks.
Alternatively, we can also think of the gene-disease association problem as
a supervised learning problem, where each gene-disease pair is represented by a num-
ber of derived features (explicitly or implicitly using a Kernel function) and then
a classifier is learnt to distinguish “positive” associations from “negatives”, us-
ing previously studied gene-disease associations, and unknown gene-disease pairs
as training data. Such an approach is taken by the recent ProDiGe method [174],
which integrates a wide variety of heterogeneous data sets and uses support vector
machines (SVMs) to identify potential gene-disease associations.
In the past decades, the growth of gene-phenotype associations in model
species has been explosive, which suggests an alternative way to find candidate
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genes for human diseases. McGary et al.[11] used this treasure trove of informa-
tion to find surprising connections between model species phenotypes and human
diseases by looking for pairs of human diseases and model phenotypes that share
a higher than expected number of orthologous genes. In this way, a number of
new, and often surprising, model systems were found for human diseases. For in-
stance, the human neural crest related developmental disorder Waardenburg syn-
drome shares gene modules with gravitropism (the ability to detect up and down)
in plants, and mammalian angiogenesis has been found to involve the same path-
ways as lovastatin sensitivity in yeast. This model species information represents
yet another form of functional connection that can be used for gene-phenotype as-
sociation.
In this work, we first propose two distinct but related GBA methods. One
is based on the Katz method[175] that has been successfully applied for link pre-
diction in social networks. The method is based on integrating functional gene
interaction networks with model species phenotype data and computing a mea-
sure of similarity based on walks of different lengths between gene and phenotype
node pairs. The second method, which we call CATAPULT (Combining dATa Across
species using Positive-Unlabeled Learning Techniques) is a supervised learning
method, wherein we represent gene-phenotype pairs in a feature space derived
from hybrid walks through the heterogeneous network used by Katz. The su-
pervised learning method falls under a class of learning methods called Positive-
Unlabeled learning methods (ProDiGe [174] also belongs in this class) since the
learning task has only positive and unlabeled examples (and no negative examples).
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The method naturally generalizes the computation of Katz on a heterogeneous net-
work by learning appropriate feature weights.
To determine if a computational method truly associates genes with dis-
eases, biological validation of the predicted associations – often by knockout stud-
ies in model systems, or through sequencing of patients – is needed. Since these
can be expensive and hard to do in a high throughput way, it is common to mea-
sure the performance of GBA methods through cross-validation. Recent work has
shown that a large fraction of the performance of GBA methods can be attributed
to the multifunctionality of genes [176]. It is not a priori clear exactly how the con-
struction of the training and the test data sets affects the measured performance
of a method. We show that Katz and CATAPULT outperform the state-of-the-art,
as measured by standard cross-validation. Furthermore, we show that standard
cross-validation is not always an appropriate yardstick for comparing the perfor-
mance of methods, and that when an alternative method for cross-validation is
used — measuring how well the methods do in case of singletons, simpler walk-
based methods often achieve better performance than supervised learning counter-
parts. We also observe that the qualitative performance of the methods correlates
better with the latter evaluation strategy. We evaluate the two proposed methods,
and compare to state-of-the-art network-based gene-disease prediction approaches
on two completely distinct sources of data, namely OMIM phenotypes and gene-
drug interactions.
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4.3 Results and Discussion
Conceptually, gene-disease association data can be thought of as a bipartite
graph, where each gene and each disease is a node, and there is an edge between a
gene node and a disease node if there is a known association between the gene and
the disease. Similarly, we can form bipartite graphs from gene-phenotype associa-
tion data of different species. By connecting a phenotype with a human gene if any
ortholog of the human gene is associated with the phenotype, we obtain a bipartite
network between human genes and phenotypes of different species. We can also
obtain a phenotype-phenotype network for a given species, where a (weighted)
edge (i, j) indicates that phenotype i is “similar” to phenotype j. Adding a gene-
gene interaction network completes a heterogeneous network of human genes and
phenotypes in a wide variety of species. It is straight-forward to define analo-
gous heterogeneous network for gene-drug interactions, by replacing gene-disease
associations data of humans with gene-drug associations. More limited heteroge-
neous networks have been considered previously in the context of gene-disease
predictions, like the network of protein-protein interactions and human diseases
considered in [173], and in the context of gene-drug predictions [177]. In this way,
the model organism phenotypes provide a new kind of links between genes, and
we can leverage the independent information hidden in the model organism data
for discovering novel associations between genes and human diseases or drugs. A
visualization of the heterogeneous network consisting of gene-gene network and
gene-phenotype networks of a few model species is presented in Figure 4.1.




























Figure 4.1: The combined network in the neighborhood of a human disease. The
local network around the human disease diabetes insipidus and two genes highly
ranked by CATAPULT, AQP1 (top ranked candidate) and MYBL2 (ranked as num-
ber 40). AQP1 is ranked higher than MYBL2 because there are more paths from
diabetes insipidus to AQP1 than to MYBL2, both through model organism pheno-
types and through the gene–gene network. Only genes and phenotypes that are
associated to both diabetes insipidus and the predicted genes AQP1 and MYBL2
are shown.
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associations as a problem of finding similarities between nodes in a heterogeneous
graph. Posing the problem in this way comes with the significant advantage that
we can leverage a large body of work in machine learning and network analysis
that deals with the problem of finding similar nodes in a graph (see, for example,
[178, 179] and references therein). In particular, we adapt the Katz method from
[178] to the heterogeneous setting. As an extension of this work, we also introduce
a supervised learning framework, CATAPULT. CATAPULT learns the importance
of features associated with node pairs, where the features are derived from walk-
based similarity measures between nodes.
Katz on the heterogeneous network
Katz is a graph-based method for finding nodes similar to a given node in
a network[175]. It has been shown to be successful for predicting friends in social
network [178]. In this paper, we show the effectiveness of the method to recom-
mend genes to given phenotype or drug. Suppose we are given an undirected,
unweighted graph with a (symmetric) adjacency matrix A, where Aij = 1 if node
i and node j are connected, and Aij = 0 otherwise. One way to find the similarity
between two (not necessarily connected) nodes i and j is to count the number of
walks of different lengths that connect i and j. This has a natural connection to ma-
trix powers since (Al)ij is exactly the number of walks of length l that connect i to
j. (Al)ij gives a measure of similarity between the nodes i and j. We want to obtain
a single similarity measure that summarizes the similarities suggested by differ-
ent walk lengths. For example, we could choose any sequence βl of non-negative
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where β is a constant that dampens contributions from longer walks. In matrix





βl Al . (4.1)
As observed by the survey article [179], we can regard S as a matrix function F(A)
where F is defined through the series expansion in (4.1), and we may allow k → ∞.
Specific choices for βl yield a variety of concrete similarity measures. A choice of
βl = βl for some β leads to the well-known Katz measure [175]:
Skatz = ∑
l≥1
βl Al = (I − βA)−1 − I , (4.2)
where β is chosen such that β < 1￿A￿2 . In the case where the connections in the
graph are weighted such that Aij is the strength of the connection between nodes
i and j, we can generalize the idea of walks using this matrix framework, by sim-
ply using the weighted adjacency matrix instead of the binary matrix. Different
ways of constructing the matrix A together with the appropriate normalizations
of the matrix lead to methods of the type used by PRINCE [172], RWRH [173],
and GeneMANIA [73], and by the famous PageRank algorithm used for web page
ranking [180]. However, we do not necessarily have to consider sums over infinite
path lengths. Paths of shorter lengths often convey more information about simi-
larity between a given pair of nodes, and contributions from longer paths become
insignificant. This suggests that we can consider a finite sum over path lengths,
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and typically small values of k (k = 3 or k = 4) are known to yield competitive
performance in the task of recommending similar nodes[181].
Let G denote gene-gene network, let P denote the bipartite network be-
tween genes and phenotypes, and let Q denote the phenotype-phenotype network.
In particular, P = [PHs PS] is a composite of gene-disease network of humans, writ-







where QHs is the similarity matrix of human diseases, and QS is that of pheno-
types of other species. In our experiments, we set QS = 0, since we do not have
information about similarity between phenotypes of other (non-human) species.
The construction of the matrices G, P and QHs will be discussed in detail in the
Methods section. We form a heterogeneous network over the gene and phenotype
nodes, similar to RWRH (which we will review briefly in the Methods section). The














Note that for smaller values of β, higher order paths contribute much less. It has
been shown that restricting the sum to a small k, i.e. a few higher order paths
works well in practice, in network link prediction and recommender systems[181].
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Letting k = 3, the block of Katz score matrix SKatz(C) corresponding to similarities
between gene nodes and human disease nodes, written SKatzHs (C), can be expressed
as:
SKatzHs (C) = βPHs + β
2(GPHs + PHsQHs)+ β3(PPTPHs +G2PHs +GPHsQHs + PHsQ2Hs)
(4.5)
where PHs and QHs denote the gene-phenotype and phenotype-phenotype net-
works of humans respectively. We use Equation (4.5) to compute scores for Katz
method in experiments.
In case of the drugs data set, we use the gene-drug network D, instead of
PHs in Equation (4.5). We do not have similarity information for drugs, and so
we set Q = 0 for experiments on drug data set. Nonetheless, we use phenotype
information from multiple species (in the composite matrix P = [D PS]) in order
to infer similarities between gene and drug nodes.
CATAPULT: A supervised approach to predicting associations
The fixed choice of parameters involved in the Katz and random walk based
approaches, as in Equation (4.4), provides a reasonable initial approach. However,
to improve performance we would like to learn the weights based on the hetero-
geneous network itself. To this end, we frame the problem of predicting potential
gene-phenotype associations as a supervised learning problem, in which we want
to learn a classifier function whose input space consists of gene-phenotype pairs
and output is a score for each gene-phenotype pair. In particular, by appropriately
defining the feature space for gene-phenotype pairs, we will see that learning a
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classifier in the constructed feature space is tantamount to learning coefficients for
Katz on the heterogeneous network computed as in Equation (4.5). Our learning
strategy is guided by the following two key characteristics of our data set:
1. For each phenotype, we only have a partial list of the associated genes. That
is, we only know of positive associations; we do not have negative associa-
tions available to us.
2. There is a large number of unlabeled gene-phenotype pairs with the prior
knowledge that most of them are, in fact, negative associations.
Classical supervised learning methods require both positive and negative exam-
ples, and therefore fall short in our case. Positive-Unlabeled learning (PU learning
for short) methods are natural for this setting. The general idea of PU learning
methods is to identify a set of negatives from the unlabeled examples and train a
supervised classifier using the positives and the identified negatives. Liu et al[182]
study different ways of choosing negatives from unlabeled examples. Biologists
believe that only a few of the large number of unobserved associations are likely
to be positive. A random sample is likely to consist mostly of negatives, which
suggests that we could randomly choose a set of examples and use the random
sample as “negative” examples to train a supervised classifier. As the examples
are not known be negative, it may be helpful to allow the classifier to not heavily
penalize the mistakes on “negatives” in the training phase. We therefore learn a bi-
ased support vector machine classifier using the positive associations and a random
sample of unlabeled associations. Recently, Mordelet et al[183] also used a random
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sample of unlabeled examples as negative sample to train a biased support vector
machine against a set of known positives. The support vector machine is biased in
the sense that false negatives (known positives classified as negatives) are penal-
ized more heavily than the false positives (“negatives” classified as positive). The
bias makes sense because the positive examples are known to be positive, while
the negatives were arbitrary and hence false positives are not to be penalized too
heavily. Note that, in principle, we could use any PU learning method (for instance,
the weighted logistic regression model proposed in [184]) to obtain a classifier for
gene-phenotype pairs.
Recent work by [183] uses the bagging technique to obtain an aggregate clas-
sifier using positive and unlabeled examples. In this approach one draws a random
bootstrap sample of a few unlabeled examples from the set of all unlabeled exam-
ples and trains a classifier treating the bootstrap sample as negatives along with
the positive examples. Bagging helps to reduce the variance in the classifier that is
induced due to the randomness in the “negative” samples. Let T be the number of
bootstraps, let A be the set of positives (i.e. gene-phenotype pairs that correspond
to known associations), let n+ denote the number of examples in A, and let U de-
note the set of unlabeled gene-phenotype pairs. We train a biased SVM, where we
use a penalty C− for false positives and relatively larger penalty C+ for false neg-
atives. Let Φ : G × P → Rd denote a feature map for the gene-phenotype pairs,
where G is the set of genes and P is the set of phenotypes (of multiple species). We
will discuss toward the end of the section how walk-based measures like Katz can
be used to obtain an embedding.
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CATAPULT (Combining dATa Across species using Positive-Unlabeled Learn-
ing Techniques) uses the biased SVM framework to classify gene-phenotype pairs
of humans and multiple other species with a single training phase, thereby making
the best use of the relation between different phenotypes. The bagging algorithm
that trains and combines several biased SVM classifiers used by CATAPULT is as
follows:
initialize θ = 0 and n(x) = 1, ∀x ∈ U .
for t = 1, 2, . . . , T:
1. Draw a bootstrap sample Ut ⊆ U of size n+.
2. Train a linear classifier θt using the positive training examples A and Ut as
negative examples by solving:
min
θ￿∈Rd
￿θ￿￿2 + C− ∑i∈Ut ξi + C+ ∑i∈P ξi (4.6)
subject to ξi ≥ 0, ∀i ∈ A ∪ Ut,
￿Φ(xi), θ￿￿ ≥ 1 − ξi, ∀i ∈ A, and
−￿Φ(xi), θ￿￿ ≥ 1 − ξi, ∀i ∈ Ut.
3. Update: θ ← θ + θt.
4. For any x ∈ U \ Ut update: n(x) ← n(x) + 1.
return s(x) = ￿θ, Φ(x)￿/n(x), ∀x ∈ U .
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We train a biased SVM given in equation (4.6) during each iteration using
all the known positive examples in A and a randomly chosen set of “negatives”
Ut ⊆ U . Positive and negative examples may not be linearly separable, and the
standard way is to penalize based on how far an example is from meeting its mar-
gin requirement, through the use of slack variables ξi. The scoring function for
iteration t is proportional to the distance of the point x from the hyperplane and is
given by the standard dot product,
￿θt, Φ(x)￿
where θt is the normal to the hyperplane learned using the random bootstrap at the
tth iteration and Φ(x) is the feature vector corresponding to x. For small number of
boostraps, say T in the range 10-100, n(x) = T for most of the unlabeled examples
and thus the procedure in effect scores (most of the) unlabeled examples using the
average hyperplane 1T ∑t θt. We set T = 30 in our experiments. Recall that, in our
framework, an instance x corresponds to a gene-phenotype pair. In contrast to the
traditional SVM classifiers that classify a pair as positive or negative based on the
sign of ￿θt, Φ(x)￿, we use the value as a score under the assumption that the further
a point is on the positive side of the hyperplane, the more likely it is to be a true
positive.
Parameters. In Equation (4.6), C+ ￿ C− are the penalties on misclassified pos-
itives and negatives respectively. The weights control the relative widths of the
margins on either sides of the hyperplane. As C+ increases from 0 to ∞, the margin
on the side of the positive examples shrinks, and as C+ → ∞, the classifier makes
96
no mistake on the positive examples. The ratio C+/C− determines the “weight” of
a positive example, and we want this to be a very high value. In our experiments,
we set C− = 1 and C+ = 10, which is found to be the best by cross-validation. The
cross-validation is done as follows: We split the positive examples into 5 folds. Us-
ing each fold as test set in turn, we do the bagging procedure with the remaining
4 folds as training positives A. For a given setting of C+ and C−, we obtain the
average recall of the final bagged classifier on the hidden test set, i.e. fraction of
number of true positives identified in the top k predictions, where k is the number
of positive examples in the test set. We choose the values of C+ and C− that achieve
the highest average recall in cross-validation1.
Features derived from hybrid walks. Before applying any supervised machine
learning approach, we need to construct features for gene-phenotype pairs. The fea-
tures that we use are all based on paths in the combined heterogeneous network.
Recall that in the Katz measure, the weights for combining the contributions from
walks of different lengths is fixed beforehand. We observe from Equation (4.5) that,
for a given length of walk, there are multiple ways of obtaining hybrid walks, as
given by the terms in the series. For a given gene-phenotype pair, different walks
of the same length, and walks of different lengths can be used as features for the
pair. Thus learning a biased SVM provides an efficient way to learn the weights,
and could help improve on the prediction performance over a particular choice of
weights, say, (β, β2, β3, . . . ) as in Katz. Clearly, the dimensionality of the feature
1Fixing C− = 1, log10 C+ was varied in the range −3,−2,−1, 0, 1, 2, 3 and log10 C+ = 1 was found









Figure 4.2: Katz features are derived by constructing walks of different kinds on
the graph. In the figure above, the disease node d1 is connected to the gene node g6
by one walk of length 2 (solid red line) and three walks of length 3 (dotted, dashed
and dashdotted red lines). This can be quickly calculated from the adjacency ma-
trix C of the graph: If Cij = 1 when there is a link between nodes i and j, and 0










space is exponential in k, length of the walk, and makes us vulnerable to the curse
of dimensionality because the examples are limited. However, taking a cue from
the fact that the weights of increasing walk lengths need to be heavily damped, we
ignore higher order terms and thereby keep the dimensionality of the feature space
small. We further decompose the features to distinguish different species, which
enables learning the contribution of each species to the prediction. The complete set
of features used by CATAPULT and the corresponding weights learned are listed in
Table 4.5. We also observe from our experiments that using species-wise features
not only lends interpretability but also improves the accuracy of the predictions,
as compared to combining features corresponding to same walk lengths. Figure
4.2 demonstrates simple walk-based features derived from the heterogeneous net-
work.
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Functional data outperforms protein-protein interactions
To see how the Katz and CATAPULT methods compare to the state-of-the-
art, we measured their recovery of genes using a cross-validation strategy similar
to the one in [174], on two different data sets, gene-disease associations from the
Online Mendelian Inheritance in Man (OMIM, [185]), and a recent drug-gene in-
teraction data set from [177]. These data sets can both be thought of as a large
collection of gene-trait pairs, either as gene-disease pairs for the OMIM data, or
target-drug pairs for the drug data set.
We compared Katz and CATAPULT to four recent methods:
1. The recently proposed ProDige method from [174], which is a support vector
machine based method that calculates similarity scores for gene pairs using
a wide variety of information sources including 21 different gene-gene func-
tional interaction networks and phenotype similarities.
2. RWRH from [173], which, like Katz uses walks on a heterogeneous gene-
disease graph to prioritize genes. It differs from the Katz method chiefly in
how the heterogeneous network is normalized. We discuss the relationship
in more detail in the Supplementary Material.
3. We include PRINCE [172] for completeness, since it is the state-of-the-art to
which both RWRH and ProDiGe were compared.
4. Finally, some recent work [176] has shown that simply by ranking based on
the degree centrality of a gene (how often it interacts with other genes, or is
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involved in diseases) can be a very competitive ranking strategy. We therefore
predict genes for diseases (or drugs) using a simple degree-based list, where
all genes are ranked by how many diseases (drugs) they are known to be
connected to, regardless of which disease (drug) the predictions are made for.
For cross-validation, we use the same testing framework as the one used in
[174]: We split the known gene-trait pairs into three equally sized groups. We hide
the associations in one group and run our methods on the remaining associations,
repeating thrice to ensure that each group is hidden exactly once. For each trait in
our data set, we order all the genes by how strongly the method predicts them to
be associated with the trait. Finally, for every gene-trait pair (g, t) in the hidden
group we record the rank of the gene g in the list associated with trait t.
The results are presented in Figure 4.3. Under this evaluation method, both
Katz and CATAPULT, which make use of much more extensive data sets than the
other methods, are quite likely to recover the hidden gene among the top 100 genes.
As can be seen from Figure 4.3, Katz and CATAPULT perform better than any of the
previously studied state-of-the-art gene-disease association methods for the OMIM
data set. CATAPULT also performs well on the drug data set, ranking the hidden
gene 14th or lower a remarkable 50% of the time. RWRH, which like Katz and
CATAPULT is a walk based method that allows paths through the gene-disease (or,
for the drug data set, gene-drug) network, also does quite well.
ProDiGe allows sharing of information between phenotypes using the simi-
larities between OMIM phenotypes, and also integrates a wide variety of functional
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Figure 4.3: Empirical cumulative distribution function for the rank of the withheld gene under
cross-validation. Left panel corresponds to evaluation of OMIM phenotypes, and the right corre-
sponds to drug data. Katz and CATAPULT methods use all species information, and HumanNet gene
network. PRINCE and RWRH methods are implemented as proposed in [172] and [173] respectively,
using the HPRD gene network. ProDiGe method is implemented as discussed in Methods section.
CATAPULT (solid red) does much better across the data sets under this evaluation scheme. In general,
the methods get high precision rates in case of the drug data. PRINCE method that does not allow
walks through species phenotypes, and OMIM phenotypes in particular, performs much worse than
other random-walk based methods. ProDiGe allows sharing of information between phenotypes
using the similarities between OMIM phenotypes and performs reasonably well, whereas there is
no such sharing possible in case of the drug data due to the absence of drug similarities. Simple
degree-based method performs poorly in general. ProDiGe and PRINCE essentially use only the
gene network information in case of the drug data.
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information in a supervised machine learning framework and performs reasonably
well on the OMIM data set. The PRINCE method, which allows some sharing of in-
formation between OMIM diseases that are phenotypically similar, performs worse
than the other random-walk based methods. Since we have no similarity informa-
tion available for the drug data, ProDiGe and PRINCE essentially use only the gene
similarity information in the drug data case. Notice that the simple degree-based
method does the worst of all methods in case of OMIM dataset, which suggests
that recommendations given by walk-based methods are more relevant and differ
significantly from simple ranking by number of known associations.
To see if the improvement in performance of Katz and CATAPULT stems
from the more extensive network used, or, in CATAPULT’s case, the increased so-
phistication of the machine learning method, we evaluated network based RWRH
and PRINCE methods using the more extensive HumanNet network instead the
HPRD network originally used. As can be seen in Figure 4.4 CATAPULT still does
better than the previous state-of-the-art using this cross-validation framework, con-
sistently in both the OMIM and drug data sets.
Top candidates are enriched for highly connected genes
To get a qualitative view of how the connectedness of genes influences the
rankings, we plotted the degree distribution of the OMIM and drug datasets in
Figure 4.5, and compared the results with the list of top candidates from CATAPULT
(see Table 4.1) and Katz (see Table 4.2).
The results for CATAPULT all seem very reasonable, from a biological stand-
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Figure 4.4: Comparison of performances using only HumanNet. Empirical cumulative distribution
function for the rank of the withheld gene under cross-validation. Left panel corresponds to evalu-
ation of OMIM phenotypes, and the right corresponds to drug data. Katz and CATAPULT methods
use all species information, and all the methods use HumanNet gene network. PRINCE and RWRH
methods are implemented as proposed in [172] and [173] respectively, but using HumanNet gene
network. ProDiGe method is implemented as discussed in Methods section. Again, as in Figure 4.3,
CATAPULT (solid red) does the best. An important observation to be made from the Figure is that
PRINCE and RWRH methods perform relatively much better than in Figure 4.3, i.e. when HPRD
network is used. (Note that there is no change to ProDiGe, Katz and CATAPULT methods; they have
identical settings as in Figure 4.3).
Figure 4.5: Distribution of the number of known phenotype associations per
gene, in OMIM diseases (left) and drugs (right).
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Table 4.1: Top 10 predictions by CATAPULT for the eight OMIM phenotypes with
most known causal genes. Any gene which is among the top 10 candidates for
more than one disease is marked in bold. CATAPULT does make a great number of
very reasonable predictions as observed below. For example, it seems quite likely
that both insulin receptor (INSR, 3643) and insulin (INS, 3630) should be associated
with insulin resistance, and that many growth factor receptors have been associ-
ated with various cancers.
Leukemia Alzheimer disease Insulin resistance Prostate cancer
MIM:601626 MIM:104300 MIM:125853 MIM:176807
FGFR3 (2261) ACE2 (59272) INSR (3643) TP53 (7157)
FGFR2 (2263) COL1A1 (1277) INS (3630) RB1 (5925)
KRAS (3845) COL1A2 (1278) PTEN (5728) CTNNB1 (1499)
TP53 (7157) KRAS (3845) TP53 (7157) BRCA1 (672)
EGFR (1956) EGFR (1956) CTNNB1 (1499) KRAS (3845)
FGFR1 (2260) TP53 (7157) KRAS (3845) PIK3CA (5290)
PTPN11 (5781) AGT (183) AKT1 (207) AKT1 (207)
CTNNB1 (1499) PLAT (5327) CREBBP (1387) INSR (3643)
INSR (3643) APOE (348) EGFR (1956) NRAS (4893)
CREBBP (1387) PTGS2 (5743) PIK3CA (5290) RAD51 (5888)
Schizophrenia Breast cancer Gastric cancer Colorectal cancer
MIM:181500 MIM:114480 MIM:137215 MIM:114500
BDNF (627) PTEN (5728) FGFR3 (2261) KRAS (3845)
NRG1 (3084) RB1 (5925) FGFR1 (2260) PTEN (5728)
CBS (875) NRAS (4893) NRAS (4893) CTNNB1 (1499)
NOS2 (4843) BRCA1 (672) HRAS (3265) HRAS (3265)
MTR (4548) HRAS (3265) EGFR (1956) CREBBP (1387)
HTR2C (3358) INSR (3643) ERBB3 (2065) RB1 (5925)
HTR2B (3357) CTNNB1 (1499) CTNNB1 (1499) FGFR3 (2261)
SLC6A4 (6532) EGFR (1956) BRAF (673) INSR (3643)
FGFR2 (2263) FGFR3 (2261) PTEN (5728) EGFR (1956)
MAT1A (4143) FGFR2 (2263) TP53 (7157) FGFR2 (2263)
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Table 4.2: Top 10 predictions by Katz for the same phenotypes as in Table 4.1. Any
gene which is among the top 10 candidates for more than one disease is marked
in bold. The Katz method shows a weaker link between the number of diseases
previously associated with a gene and its presence in the list, while still giving a
number of very likely candidates.
Leukemia Alzheimer disease Insulin resistance Prostate cancer
MIM:601626 MIM:104300 MIM:125853 MIM:176807
IL3 (3562) APLP2 (334) INS (3630) BRCA1 (672)
SOCS1 (8651) HSPA8 (3312) AKT1 (207) TP53 (7157)
GRB2 (2885) CTSB (1508) INSR (3643) RAD51 (5888)
NOP2 (4839) LRP1 (4035) GRB2 (2885) EGFR (1956)
CSF2RB (1439) NID1 (4811) IGF1R (3480) ATM (472)
PPM1L (151742) APOE (348) CTNNB1 (1499) AKT1 (207)
PTPN6 (5777) BDKRB2 (624) CREBBP (1387) MAX (4149)
MYH11 (4629) PLAUR (5329) PIK3CA (5290) CDK1 (983)
PPM1E (22843) APLP1 (333) TYK2 (7297) PIK3CA (5290)
PPM1B (5495) CAV1 (857) GPD1 (2819) CSNK2A1 (1457)
Schizophrenia Breast cancer Gastric cancer Colorectal cancer
MIM:181500 MIM:114480 MIM:137215 MIM:114500
DRD2 (1813) BRCA1 (672) GRB2 (2885) PTEN (5728)
AHCY (191) IRS1 (3667) EGFR (1956) CTNNB1 (1499)
ADRA2B (151) MRE11A (4361) NRAS (4893) CDK1 (983)
XRN2 (22803) INSR (3643) IRS1 (3667) GSK3B (2932)
MAT1A (4143) CHEK1 (1111) MAPK1 (5594) CDC20 (991)
MAT2A (4144) ATR (545) PTPN11 (5781) 5111 (5111)
CHI3L2 (1117) PTEN (5728) HRAS (3265) EGF (1950)
TSNAX (7257) MAPK1 (5594) MAP2K2 (5605) PTTG1 (9232)
DDC (1644) MAPK3 (5595) MAP2K1 (5604) IGF1R (3480)
MAOB (4129) UBE2I (7329) SOS1 (6654) FOXO3 (2309)
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point. For example, CATAPULT identifies APOE, which even though is not linked to
“Susceptibility to Alzheimer’s disease” OMIM record (MIM:104300), is well known
to be associated with Alzheimer’s disease and is associated with two other OMIM
records involving Alzheimer’s (MIM:104310 and MIM:606889). BRCA1 is associ-
ated with “Breast-ovarian cancer, familial 1” (MIM:604370), not the record we show
in Table 4.1 (“Breast cancer, susceptibility to”, MIM:114480), even so, it is ranked
very highly among the candidate genes for breast cancer. Many of the other can-
didate genes listed are similarly very likely to be involved in the etiology of the
diseases, like TP53 and KRAS for many cancers. Indeed, what might be the most
surprising about the results is how completely non-surprising they seem. Further-
more, there is a very high degree of overlap between the top predictions. Indeed,
almost all the top 10 candidate genes for the eight diseases shown are shared be-
tween at least two of the eight diseases for CATAPULT. Moreover, when study-
ing the results for the same diseases for ProDiGe, given in [174], we see the same
pattern as we see for CATAPULT – a strong enrichment for genes that are already
known to be associated with many diseases.
In contrast, the results for Katz (Table 4.2) contain comparatively fewer of
these very obvious predictions, and a much lower degree of overlap between the
top predictions. There is still a certain number of predictions shared, particularly
between the different cancers and type 2 diabetes. However, the predictions made
seem to reflect the relevance of a gene to the specific disease more than the overall
likelihood that a gene is associated with any disease.
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Validation on singletons highlights methods that detect novelty
The cross-validation evaluation shown in Figures 4.3 and 4.4 clearly shows
that CATAPULT is better at recapitulating the genes known to be involved in a dis-
ease than any of the other methods. However, recapitulation of previously known
results is rarely the goal in biology. We therefore seek a measure that would reflect
how suited a method is for correctly identifying novel associations.
There are two ways in which one could envision for doing this in a cross-
validation framework – either one could hide all associations between a given gene
and diseases, thereby hoping to put it on equal footing with genes still unstudied,
or one restricts the cross-validation to genes that are only associated with a single
phenotype. There are clear advantages to both approaches. The former approach
allows us to do validation on a larger set, namely all known gene-disease associa-
tions, and thereby reach stronger statistical strength. The latter approach has more
subtle, but in our opinion greater, advantage. The biases that favor already well
studied genes are not only present in the gene-disease association data, but also in
the data that gives rise small differences between genes that have been studied well
and poorly characterized genes. By only looking at the least studied genes in our
data set for which we do have known gene-disease associations, we can minimize
the risk that any signal that we detect is merely some general characteristic of well
studied genes, and instead actually measure how well a method can detect truly
novel gene disease associations.
We tested all the methods using cross-validation restricted to genes with
only a single disease (or drug) association. The results are presented in Figure 4.6.
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CATAPULT does worse on singleton phenotypes and drugs, as compared to Figure
4.4 (that uses the same setting for all the methods). PRINCE and ProDiGe meth-
ods are consistent with (and sometimes perform slightly better than) the three-fold
cross-validation evaluation. RWRH and Katz perform better than the supervised
learning methods ProDiGe and CATAPULT in this evaluation sheme. The fact that
PRINCE performs the best on singletons in case of drug data is surprising, given
that the only information it uses is the HumanNet gene network. Simpler random-
walk based methods in general perform better than the supervised counterparts,
and do so consistently in two completely distinct data sets. Furthermore, we find
that the qualitative results of the methods (Tables 4.1 and 4.2) are in line with the
observed performance of the methods on singleton genes.
Conclusions
We have proposed two methods for inferring gene-phenotype associations,
Katz and CATAPULT. Katz is motivated by social network link prediction and
CATAPULT is a supervised extension to Katz which learns the weights for walks
that have different lengths and that involve different kinds of data. While CAT-
APULT significantly outperforms other state-of-the-art gene-phenotype association
methods using a conventional cross-validation evaluation strategy, such a cross-
validation strategy does not reflect the properties of a scenario in which one wants
to predict novel gene-phenotype associations involving less studied genes.
To address such cases, we propose a cross-validation approach restricted to
relatively little studied genes. In this framework the Katz method and the related
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Figure 4.6: Empirical cumulative distribution function for the rank of the withheld gene, under
evaluation of singleton phenotypes and drugs. Left panel corresponds to evaluation of OMIM
phenotypes, and the right corresponds to drug data. Katz and CATAPULT methods use all species in-
formation, and all the methods use HumanNet gene network. PRINCE and RWRH methods are im-
plemented as proposed in [172] and [173] respectively, but using HumanNet gene network. ProDiGe
method is implemented as discussed in Methods section. CATAPULT (solid red) does worse on single-
ton phenotypes and drugs, as compared to Figure 4.4 (that uses the same setting for all the methods).
PRINCE and ProDiGe methods are consistent with (and sometimes perform slightly better than) the
full cross-validation evaluation. RWRH and Katz perform better than the supervised learning meth-
ods ProDiGe and CATAPULT in this evaluation sheme. The fact that PRINCE performs the best on
singletons in case of drug data is surprising, given that the only information it uses in the HumanNet
gene network.
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RWRH and Prince methods do better than CATAPULT, indicating that if the objec-
tive is to find new gene-disease or gene-drug associations involving genes not yet
well studied, these approaches are more appropriate.
We therefore conclude that comparisons of gene-phenotype methods do not
necessarily lead to a simple ordering from best to worst. A method like CATAPULT
is clearly preferable when the goal is to recapitulate the currently known gene-
phenotype associations. On the other hand, in cases where a researcher wants to
find new directions for research or find previously unknown biology, a method like
Katz, which does better when tested on genes only associated with a single disease,
is clearly preferable to a method like CATAPULT, which emphasises genes that are
“important” in general. In the future, it is therefore important that descriptions of
new gene-phenotype association methods include a careful discussion on how the
method is intended to be used.
4.4 Materials and Methods
Gene Networks
We use two sources of gene-gene interactions in our experiments.
1. HumanNet: A large-scale functional gene network which incorporates multi-
ple data sets, including mRNA expression, protein-protein interactions, pro-
tein complex data, and comparative genomics (but not disease or pheno-
type data) obtained from [21]. HumanNet contains 21 different data sources,
which are combined into one integrated network using a regularized regres-
sion scheme trained on KEGG pathways.
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2. HPRD network [186]: Most of the published work on predicting gene-disease
associations [170–173, 187] use the HPRD network. The network data was
downloaded from [169]. The edges in the HPRD network are unweighted,
and the network is much sparser than HumanNet. In particular, the HPRD
network has 56,661 associations compared to 733,836 (weighted) associations
for HumanNet.
Phenotypes from other (non-human) species
We collected gene-phenotype associations from literature and public data-
bases for eight different (non-human) species: plant (Arabidopsis thaliana, from TAIR
[164]), worm (Caenorhabditis elegans from WormBase [188] and [159]), fruit fly (Droso-
phila melanogaster from FlyBase [189]), mouse (Mus musculus from MGD [190]),
yeast (Saccharomyces cerevisiae [9, 191–193]), Escherichia coli [161], zebrafish (Danio
rerio from ZFIN [194]), and chicken (Gallus gallus from GEISHA [195]). We deter-
mined orthology relationships between genes in model species and human using
INPARANOID [112]. Detailed description on the extraction of most datasets can
be found in [11] and the resulting dataset has been summarized in Table 4.3.
E. coli phenotypes were obtained from the file ‘coli FinalData2.txt’ on May
20, 2011 [161]; we sorted each gene’s phenomic profile by score, taking both the top
and bottom forty conditions and assigning them to the gene. Thus, we considered
each condition to be a phenotype, and the genes associated with that phenotype
were those genes whose growth was most affected (either positively or negatively)
in the corresponding condition. As a proxy for chicken phenotypes, tissue specific
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mRNA expression patterns were derived from GEISHA in situ hybridization an-
notations, which were kindly provided in XML format on June 24, 2011. Genes
were sorted into multiple bins by stage, by location, and by location and stage to-
gether. If there were more than fifty genes in a specific location and more than
three at a specific stage at that location, a new phenotype was created (“anatom-
ical location at stage x”); regardless, each location became a phenotype. Worm
phenotypes from [159] were divided into two datasets, ‘green-broad’ and ‘green-
specific’, based on the broad and specific phenotypes presented in that work. GO
biological processes from TAIR and ZFIN were processed in the same manner. We
kept only those annotations with evidence codes IMP, IDA, IPI, IGI, TAS, NAS, IC,
and IEP. For TAIR, we used ‘ATH GO GOSLIM.txt’, downloaded on August 23rd,
2010; and for ZFIN, we obtained GO biological processes from geneontology.org
(‘gene association.zfin.gz’) on April 26th, 2011.
Evaluation data
We perform experiments on two types of data sources:
• OMIM Phenotypes: We obtained new OMIM data from the Online Mendelian
Inheritance in Man (OMIM) project [185] on August 11, 2011. OMIM pheno-
types have become the standard data set for the evaluation of prediction of
gene-disease associations[170–174, 187]. All the compared methods use sim-
ilarities between phenotypes. We obtained similarities between OMIM phe-
notypes from [196].
• Drug data: This includes four benchmark data sets of Drug-Target interac-
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tions in humans involving enzymes, ion channels, G-protein-coupled recep-
tors (GPCRs) and nuclear receptors, first studied in [197]. Refer to Table 4.4
for statistics on the data sets. The data sets were made available by [177] and
downloaded from [198].
Problem setup and Notation
Let G denote the set of human genes and for each species i ∈ S = {Hs, At,
Ce, Dm, Dr, Ec, Gg, Mm, Sc}, let Pi denote the set of phenotypes for the species.
Refer Table 4.3 for descriptions of the species and a summary of the data sets. Also,
let D denote the set of drugs (i.e. the four benchmark data sets mentioned in Table
4.4). For each species i ∈ S , we constructed a gene-phenotype association matrix
Pi ∈ R|G|×|Pi |, such that (Pi)gp = 1 if gene g is associated with phenotype p or 0 oth-
erwise. For methods using multiple species, we used PS = [PAt PCe PDm . . . PSc]
and recall that P = [PHs PS] in Equation (4.5). Similarly, we constructed a drug-
gene interaction matrix D using drugs data where Dgd = 1 if gene g is associated
with drug d (note that d can be one of enzymes, ion channels, GPCRs or nuclear
receptors) and Dgd = 0 otherwise. Using the two types of gene-gene interaction
data HPRD and HumanNet, we constructed matrices GHPRD ∈ {0, 1}|G|×|G|, and
GHumanNet ∈ R|G|×|G| respectively. We constructed a phenotype-phenotype net-
work QHs ∈ R|PHs|×|PHs| (i.e. corresponding to humans) using OMIM phenotype
similarities obtained from [196]. For experiments with drug data, we did not have
access to any such similarity score for drug pairs, so we set the drug-drug network
to 0. The same is the case for other species data as well, and we set the correspond-
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ing entries in Q to be 0, both for the experiments with OMIM and for the drug data.
Following the approach in [172], we apply a logistic transformation to the similar-
ities QHs, i.e. L(x) = 11+exp(cx+d) where x represents an entry of QHs. For setting c
and d, see [172].
RWRH
Random Walks with Restart on Heterogeneous network (RWRH) is an al-
gorithm for predicting gene-disease associations proposed by Li and Patra[173].
RWRH performs a random walk on a heterogeneous network of gene interactions
(HPRD) and human diseases (we used OMIM phenotypes and the drug data de-
scribed above). The method constructs a heterogeneous network using the GHPRD, PHs
and QHs networks and runs a personalized PageRank computation, a popular
choice for ranking documents and web pages, on the network. The random walk is
started from a set of seed nodes, which for a phenotype p is the set of genes known
to be associated with p, and gene nodes are ranked by the probability that a random
walker is at a given gene, under the steady state distribution for the random walk.







where G̃ is the gene-gene interactions matrix, with rows normalized by row-degree
and scaled so that ∑j Cij = 1, and λ is the probability that the random walker
jumps from a gene node to a phenotype node (or vice versa). In [173], PHs is the
gene-disease association matrix corresponding to OMIM phenotypes, QHs is the
corresponding similarity matrix, and G̃ is derived from GHPRD. Genes are ranked
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for a given disease p using the steady state vector s given by :
s = (1 − γ)CTs + γp0 (4.8)
where p0 is the restart vector (indicator vector of the set of seed nodes known to be
associated with p). In our experiments, we use OMIM phenotypes matrix PHs as
well as the gene-drug interaction matrix D, and two types of gene-gene matrices
to derive G̃. Recall that in the latter case, we do not have similarity information
for drugs, and therefore we set drug-drug similarity matrix to 0. It is also straight-
forward to incorporate phenotype data from multiple species in the method, by
replacing PHs with P = [PHs PS], analagous to our Katz method.
PRINCE
The PRINCE method, proposed by Vanunu et al. [172], is another graph-
based method that can be thought of as a special case of RWRH. Here, the random
walk is only over the gene interaction network instead of the heterogeneous net-
work. The phenotype similarities are incorporated in the restart vector. The vector
of scores computed by PRINCE for a given phenotype p can be expressed as
sPRINCE = (I − γG)−1 p̃ (4.9)
where p̃ is the smoothed phenotype, i.e. p̃i = (QHs)qp where q is the phenotype
most similar to p. Note that, similarly, the scores computed by RWRH can be writ-
ten succinctly as
sRWRH = (I − γC)−1 p (4.10)
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where C is defined in Equation (4.7). The absence of similarity information for other
(non-human) species phenotypes and drugs renders direct extension of PRINCE to
multiple species data inconsequential. We must emphasize here that PRINCE does
not allow walks through the gene-phenotype interaction network or the phenotype-
phenotype interaction network. As a result, availability of other species data be-
comes irrelevant when predicting genes for a given disease (or other drug data in
case of predicting for a given drug).
ProDiGe
The ProDiGe method, proposed by Mordelet and Vert [174], makes use of
positive-unlabeled learning and a multiple kernel learning framework to integrate
information from multiple types of gene interaction data and phenotype similar-
ities. Kernels are defined over pairs of genes and pairs of phenotypes, and the
kernel value for a pair of gene-phenotype pairs is derived using the individual
gene and phenotype kernels. In particular, let Kgene(g, g￿) denote the kernel for
genes, and Kphenotype(p, p￿) denote that for phenotypes. Then, the kernel for the
pairs ((g, p), (g￿, p￿)) is simply,
Kpair((g, p), (g￿, p￿)) = Kgene(g, g￿)× Kphenotype(p, p￿) (4.11)
The gene-phenotype pairs are then classified using a support vector machine using
the constructed kernel. Note that the method proposed in [174] does not use any
other species phenotype information, but only the OMIM phenotypes. In our ex-
periments on OMIM phenotypes, we used the Kgene and Kphenotype provided by the





1 if d = d￿,
0 otherwise.
For Kgene and Kphenotype, we used the kernels provided by Mordelet2.
Implementation
We implemented all the methods in Matlab. Our implementation of CAT-
APULT can be downloaded from the web3. The training time for our method is
essentially the time taken for constructing the features. Obtaining features for all
gene-phenotype pairs takes about 20 minutes. Training and bagging biased SVMs
are much faster, and take a few seconds per iteration on our cluster machines (2.8
GHz processor, 32GB RAM). We download the MATLAB code for Li and Patra’s
RWRH method4, and the code for Mordelet and Vert’s ProDiGe5. For PRINCE, we
use MATLAB code kindly provided by Oded Magger.
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Table 4.3: Different species used for inferring gene-phenotype associations in
the proposed methods Katz and CATAPULT, and sizes of the gene-phenotype net-
works for the species, restricted to orthologs of human genes. The total number of
human genes with any kind of phenotype annotation is 12331.
Index Species # Phenotypes # Associations
1 Human (Hs) 3,209 3,954
2 Plant (At) 1,137 12,010
3 Worm (Ce) 744 30,519
4 Fly (Dm) 2,503 68,525
5 Zebrafish (Dr) 1,143 4,500
6 E.coli (Ec) 324 72,846
7 Chicken (Gg) 1,188 22,150
8 Mouse (Mm) 4,662 75,199
9 Yeast (Sc) 1,243 73,284
Table 4.4: Benchmark Drug data sets used for evaluation, obtained from [197].
Index Type # Drugs # Associations
1 Enzymes 445 2,926
2 Ion Channels 210 1,476
3 GPCRs 223 635
4 Nuclear Receptors 54 90
Award to ISD.
4.6 Supplementary Material
Relationship between Katz on the heterogenous network and RWRH
Restricting P to human phenotypes, i.e. letting P = PHs, and weighing
P and P￿ by λ in the heterogeneous network C where 0 < λ < 1 is the jump-
ing probability, in Equation (4.3), we get the heterogeneous network construction
used in [173]. The random walk with restarts method of [173] when extended to
our heterogenous network turns out to be equivalent to Katz measure provided the
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Table 4.5: Weights learned for different features by CATAPULT using the biased SVM with bag-
ging procedure, using the HumanNet gene network. Two important observations are: (1) Features
corresponding to higher path lengths receive relatively much smaller weights. (2) Features corre-
sponding to different species receive different weights, in particular, features derived from mouse
phenotypes get the highest weights, which makes sense given the relative evolutionary proximity
between humans and mice.




























































































GPHs 1.23 G3PHs 0.57











columns of the combined matrix C are normalized appropriately. The equivalence
is shown below. Let CN denote the normalized matrix, with the different blocks
























where p refers to one of the remaining |PHs| columns of C, with the understanding
that if a gene is not known to be associated to any phenotype (i.e. ￿Pg,:￿ = 0) then
we will simply use λ = 1 for that gene. Case ￿Q:,p￿ = 0 is handled similarly. Then
we consider the evolution:
vT+1 = βCNvT + (1 − β)CN:,p
where CN:,p is simply a probability distribution with equal mass on all genes known
to be associated with a phenotype p of interest, and mass on the diseases related
to p . The genes are then ranked in the order of the mass that is assigned to them
under the steady state distribution v∞ of this evolution. The steady state vector v∞
should satisfy
v∞ = βCNv∞ + (1 − β)CN:,p
which readily yields
v∞ = (1 − β)[I − βCN ]−1CN:,p .
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Thus the score matrix computed by RWRH can be written as6,
β[I − βCN ]−1CN = βCN + β2(CN)2 + β3(CN)3 + . . . .
which is exactly Katz but on the normalized matrix CN instead of C itself.
Relationship between Katz on the heterogenous network and PRINCE
Examining the computation of Katz on heterogeneous network closely yields
an interesting connection to PRINCE. As k → ∞ in Equation (4.4) and for appro-
priate choice of β, let






where it can be shown that
SGP = Skatz(G)P
￿
I − (Q + P￿Skatz(G)P)
￿−1
. (4.12)
Note how the Katz similarity matrix Skatz(G) = (I − βG)−1 for the (weighted)
gene-gene network λGG itself appears in the expression above. The expression
above takes into account all kinds of paths in the combined network that start in
gene nodes and end up in human phenotype nodes. The corresponding score ma-
trix computed by PRINCE[172] method can be generalized as
SPRINCEGP = S
Katz(G)PQ
Note that it is a form a generalization, as PRINCE smoothes a given phenotype
using its most similar neighbor, whereas the term PQ in Equation (4.6) combines
6Multiplying either sides of the equation by constant factor β/(1 − β) does not affect the ranking
of candidates.
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all the neighbors linearly. Also note that the expression should strictly have PHs
and QHs instead of P and Q as [172] uses only human phenotypes data. However,
writing this way enables comparison to the expression corresponding to Katz on
heterogeneous network given in Equation (4.12). Clearly, Katz on heterogeneous
network generalizes PRINCE method. In particular we observe that while PRINCE
relies on the matrix Q to obtain “smoothed” phenotypes by sharing information




Conclusions and musings about the future
The genomic era has completely revolutionized the study of the genetic ba-
sis for all kinds of human diseases and disorders. Cheap genotyping platforms, like
SNP chips, have made it possible to find subtle genetic risk factors by genotyping
huge populations and millions of commonly varying loci. At the other end of the
spectrum, modern sequencing technology allows us to cheaply sequence candidate
disease genes for very rare (or unique) mutations.
Yet, despite this deluge of data, the results of the genotyping efforts of the
last decade have often met with disappointment. Genome-wide association stud-
ies have only found a small fraction of the genetic basis for common diseases, sug-
gesting that much of the genetic risk lies in rarer mutations (the so-called “missing
heritability”). Candidate gene sequencing studies often fail to find any interesting
mutations, simply because the wrong candidate gene was sequenced.
In this thesis, I have used the information encoded by HumanNet to ad-
dress both of these problems, to find genes weakly associated with diseases in
GWAS in chapter 2 and to prioritize candidate genes to sequence for rare muta-
tions in chapters 3 and 4. The “guilt-by-association” framework I have employed
is not only a powerful tool for identifying new gene-disease associations, it also
gives context to the predictions it generates; by studying the network neighbours of
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the genes predicted and already associated with a disease, we get an idea of what
pathways and biological processes are involved in the disease.
In the future, the distinction between the GWAS setting and the candidate
gene sequencing setting will become weaker and weaker. With falling sequenc-
ing costs the need to use a SNP chip instead of fully sequencing the genomes of
study participants will disappear. In the same way, the need to restrict sequencing
to only a few candidate genes will disappear. It will therefore be necessary to let
the methods for future GWAS analysis borrow from the tools we use to prioritize
rare candidate genes, and to expand the techniques used to find rare mutations in
Mendelian disorders so that they can be used to analyse genome-wide data. This
work shows that network based GBA is a powerful tool at both ends of this spec-
trum, and will therefore be an important part in this future statistical framework.
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Appendix A
Network-smoothed sparse regression for GWAS
A.1 Background
I have described the idea behind GWAS in the introduction. Briefly, at each
SNP, a person can be either homozygous for the major allele, homozygous for the
minor allele, or heterozygous. The idea underlying GWAS is that genetic loci that
affect disease state will be distributed differently among the cases and among the
controls, and by looking at the genes located close to these markers we can learn
what causes the disease. In the traditional analysis of GWAS data, this difference
has been measured by means of χ2 tests or by Bayesian modeling, and a p-value
or log-odds Bayes factor has been given for each SNP to indicate how likely it is
to be involved in the disease. I will here employ a different approach, inspired
by compressed sensing and ￿1 regularization. This approach was first described
in [55]. I will give a brief overview of the approach, and then state the modifica-
tions I proposed to it, and hurdles I encountered. However, in the spring of 2012 I
learned that Alexis Battle in Daphne Koller’s group had already tried a very similar
approach, and was very close to publishing, which made me abandon this line of
inquiry.
If we let the number of subjects in the study be n, and the number of SNPs
be N, we can encode this information as a big matrix A, where dim A = n× N, and
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aij ∈ {−1, 0,+1} depending on if subject i is homozygous (±1) or heterozygous (0)
at SNP j.
A.2 Linear regression
If we assume that the loci affect the phenotype in an additive, linear, man-
ner we can model the phenotype value yi of patient i as
yi = ∑
j
aijxj + µ + ei,
or, in matrix form,
y = Ax + µ + e,
where xj is effect size for locus j, µ is the population mean for the phenotype and
e is non-genetic factors, which we will model as noise. If we assume that only a
small number of loci (on the order of a few hundred) affect the disease, x is a sparse




where ￿Ax + µ − y￿2 < ￿.
This is the lasso, and has been tried in the context of GWAS by Wu et al. in [55],
with promising results.
A.3 Logistic regression
However, most GWAS don’t deal with continuous phenotypes. Instead,
they are of the case-control variety. For such settings, logistic regression might be
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or, equivalently, maximize the likelihood of the data. We can give this a more
compressed flavor by adding a regularizing term to it, which makes sense given










A.4 Network smoothing penalties
One way to improve the performance of these classifiers is to add more
data of some form, which is the approach I (and independently Battle) settled on.
One obvious candidate for a good data source would be a gene-gene interaction
network, and then add a penalty when the total effect of all the SNPs associated
with a gene differs to much from the total effect of SNPs associated with network









where x is the SNP effect size, y the measured phenotypic value, A the genotype
matrix and Γ is a network laplacian derived from HumanNet, that we’re smoothing
over. If we expand the norm squared, we get
||Ax − y||22 + βxTΓx = xT AT Ax − 2yAx + y2 + xTΓx.
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A.5 Approach
However, this drives the x-es to have the same sign if they are similar. In my
application that doesn’t make any sense, since the sign is an artifact of the encoding









Clearly, this is not convex . However, I can find a convex relaxation. Consider the





||A(x+ − x−)− y||22 + λ||x+ − x−||1 +
1
2
(x+ − x−)TΓ(x+ − x−),





||A(x+ − x−)− y||22 + λ||x+ + x−||1 +
1
2
(x+ + x−)TΓ(x+ + x−),
where
(i) x+ ≥ 0, (ii) x+i > 0 ⇒ x−i = 0,
(iii) x− ≥ 0, (iv) x−i > 0 ⇒ x+i = 0.
If we relax the constraints by simply dropping conditions (ii) and (iv), we get a










where |wi| ≤ zi, which is clearly convex.
A.6 Problem
The network smoothing seems like it should enforce the kind of structure I
want. However, since it smooths over all values, nodes that are highly connected
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will be pulled down by the zeros they’re surrounded by. I’m not sure how to deal
with that. One could normalize the links for all nodes. This breaks symmetry of
the network, but maybe that’s not a big deal. Another way could be to choose the
penalties such that all nodes are a priori equally likely to be pulled down. That is,
if all nodes are zero, the slope to increase a certain node is independent of the node.
Since the slope at a node i is
∑
j
Aij(Ajkwk − yj) + λisign(zi) + Γijzj
we could choose λi to be Λ − Γii or something like it.
While I was dealing with this problem, I saw a talk by Alexis Battle, and
realized she already had a working network-smoothed GWAS regression model,
and had tried it on the same data set I was planning to use.
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[112] Ostlund, G., Schmitt, T., Forslund, K., Köstler, T. et al. InParanoid 7: new algorithms and tools
for eukaryotic orthology analysis. Nucleic acids research 38, D196–203 (2010).
[113] Wang, X., Sun, W., Zhu, X., Li, L. et al. Association between the gamma-aminobutyric acid type
B receptor 1 and 2 gene polymorphisms and mesial temporal lobe epilepsy in a Han Chinese
population. Epilepsy research 81, 198–203 (2008).
[114] Glasscock, E., Yoo, J. W., Chen, T. T., Klassen, T. L. & Noebels, J. L. Kv1.1 potassium chan-
nel deficiency reveals brain-driven cardiac dysfunction as a candidate mechanism for sudden
unexplained death in epilepsy. The Journal of neuroscience : the official journal of the Society for
Neuroscience 30, 5167–75 (2010).
[115] Butt, S. J. B., Sousa, V. H., Fuccillo, M. V., Hjerling-Leffler, J. et al. The requirement of Nkx2-1
in the temporal specification of cortical interneuron subtypes. Neuron 59, 722–32 (2008).
[116] Ratnapriya, R., Vijai, J., Kadandale, J. S. et al. A locus for juvenile myoclonic epilepsy maps to
2q33-q36. Human genetics 128, 123–30 (2010).
[117] Wyneken, U., Smalla, K. H., Marengo, J. J., Soto, D. et al. Kainate-induced seizures alter
protein composition and N-methyl-D-aspartate receptor function of rat forebrain postsynaptic
densities. Neuroscience 102, 65–74 (2001).
[118] Douaud, M., Feve, K., Pituello, F., Gourichon, D. et al. Epilepsy Caused by an Abnormal
Alternative Splicing with Dosage Effect of the SV2A Gene in a Chicken Model. PloS one 6,
e26932 (2011).
[119] Kaminski, R. M., Gillard, M., Leclercq, K., Hanon, E. et al. Proepileptic phenotype of SV2A-
deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam. Epilepsia 50,
1729–40 (2009).
142
[120] Janz, R., Goda, Y., Geppert, M., Missler, M. & Südhof, T. C. SV2A and SV2B function as redun-
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